Podcasts about National Health Service

This week, the speaker is mourning the loss of Dolly Parton, but also reflecting on the recent passing of Tim Curry. t's a celebrity trifecta that's got everyone talking. But amidst the sadness, the speaker is also sounding the alarm on the potential consequences of a single-payer healthcare system. With the rise of Medicare for All, the speaker is joined by Sally Pipes, a healthcare expert from the Pacific Research Institute, to discuss the realities of a government-run healthcare system. They delve into the failures of the UK's National Health Service and the Canadian healthcare system, highlighting the long waiting times, low doctor morale, and the financial costs associated with a single-payer system. The speaker also touches on the topic of assimilation, discussing the challenges of integrating migrants into Western culture. They share a shocking statistic from Switzerland, where 80.5% of asylum seekers from North African countries were accused of one or more offenses. The speaker questions whether this is a reflection of the culture of the migrants or a sign of a larger problem with the system. Additionally, they discuss the importance of understanding the differences between Western values and the values of other cultures. In a lighter moment, the speaker talks about the new features being added to Uber, including a teen account and a live streaming feature that allows parents to monitor their child's ride. They also discuss the importance of being aware of the potential risks of artificial intelligence, citing a recent essay by Bill Gates on the topic. Tune in to hear the full episode and learn more about the celebrity trifecta, the future of healthcare, and the importance of understanding cultural differences.See omnystudio.com/listener for privacy information.

"In my home country, they call me a 'bornfree'." Simukai Chigudu was born in Zimbabwe, two years after the end of its bitter war of liberation - a war in which his father had fought. This is the story of his childhood journey through the chaos of that new country's birth to Britain, where he arrived alone, a teenager, burning with ambition but utterly lost in ways he had yet even to discover. Told with astonishing insight, his memoir describes the drama of his quest to belong and to succeed, and how his worldview was both shaped and shattered by Britain, ultimately setting him on a quest to uncover the truth of his parents' past. In excavating their story alongside his own, he brings us closer than ever before to understanding one of the greatest upheavals in modern times - the freeing of a continent from colonial rule - not as history or politics but as a psychological and emotional force, one that divides families from within, even while those same divisions bind them fiercely together across time. Read the transcript here. Simukai Chigudu is Associate Professor of African Politics at the Oxford Department of International Development and Fellow of St Antony's College, Oxford University. He is broadly interested in the politics of global health and epidemics, race and identity, citizenship and activist movements, with a regional focus on Africa and the African diaspora. Simukai is the author of The Political Life of an Epidemic: Cholera, Crisis and Citizenship in Zimbabwe (Cambridge University Press, 2020), an examination of the social and political causes and consequences of Zimbabwe's catastrophic cholera outbreak in 2008/09, the most extensive in African history. This monograph won the Theodore J. Lowi First Book Award from the American and International Political Science Associations. He has conducted research in Zimbabwe, Uganda, The Gambia, and Tanzania, and has publications in several leading social science and medical journals. Simukai has recently published his first book for the trade, Chasing Freedom: Coming of Age at the End of Empire, published by The Bodley Head and Crown in March 2026. This book combines memoir, political history and cultural criticism to show how colonialism continues to shape politics, society and culture in Africa and in Britain and to explore what it really means to decolonise. Prior to working in academia, Simukai was a medical doctor in the UK's National Health Service. He holds a DPhil in International Development from the Oxford University for which he was awarded the biennial Audrey Richards Prize for the best doctoral thesis in African Studies examined at a UK university. Simukai teaches on the MPhil in Development Studies and supervises DPhil students. Ayisha Osori is a lawyer and Director at Open Society Foundations Ideas Workshop. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

"In my home country, they call me a 'bornfree'." Simukai Chigudu was born in Zimbabwe, two years after the end of its bitter war of liberation - a war in which his father had fought. This is the story of his childhood journey through the chaos of that new country's birth to Britain, where he arrived alone, a teenager, burning with ambition but utterly lost in ways he had yet even to discover. Told with astonishing insight, his memoir describes the drama of his quest to belong and to succeed, and how his worldview was both shaped and shattered by Britain, ultimately setting him on a quest to uncover the truth of his parents' past. In excavating their story alongside his own, he brings us closer than ever before to understanding one of the greatest upheavals in modern times - the freeing of a continent from colonial rule - not as history or politics but as a psychological and emotional force, one that divides families from within, even while those same divisions bind them fiercely together across time. Read the transcript here. Simukai Chigudu is Associate Professor of African Politics at the Oxford Department of International Development and Fellow of St Antony's College, Oxford University. He is broadly interested in the politics of global health and epidemics, race and identity, citizenship and activist movements, with a regional focus on Africa and the African diaspora. Simukai is the author of The Political Life of an Epidemic: Cholera, Crisis and Citizenship in Zimbabwe (Cambridge University Press, 2020), an examination of the social and political causes and consequences of Zimbabwe's catastrophic cholera outbreak in 2008/09, the most extensive in African history. This monograph won the Theodore J. Lowi First Book Award from the American and International Political Science Associations. He has conducted research in Zimbabwe, Uganda, The Gambia, and Tanzania, and has publications in several leading social science and medical journals. Simukai has recently published his first book for the trade, Chasing Freedom: Coming of Age at the End of Empire, published by The Bodley Head and Crown in March 2026. This book combines memoir, political history and cultural criticism to show how colonialism continues to shape politics, society and culture in Africa and in Britain and to explore what it really means to decolonise. Prior to working in academia, Simukai was a medical doctor in the UK's National Health Service. He holds a DPhil in International Development from the Oxford University for which he was awarded the biennial Audrey Richards Prize for the best doctoral thesis in African Studies examined at a UK university. Simukai teaches on the MPhil in Development Studies and supervises DPhil students. Ayisha Osori is a lawyer and Director at Open Society Foundations Ideas Workshop. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/african-studies

"In my home country, they call me a 'bornfree'." Simukai Chigudu was born in Zimbabwe, two years after the end of its bitter war of liberation - a war in which his father had fought. This is the story of his childhood journey through the chaos of that new country's birth to Britain, where he arrived alone, a teenager, burning with ambition but utterly lost in ways he had yet even to discover. Told with astonishing insight, his memoir describes the drama of his quest to belong and to succeed, and how his worldview was both shaped and shattered by Britain, ultimately setting him on a quest to uncover the truth of his parents' past. In excavating their story alongside his own, he brings us closer than ever before to understanding one of the greatest upheavals in modern times - the freeing of a continent from colonial rule - not as history or politics but as a psychological and emotional force, one that divides families from within, even while those same divisions bind them fiercely together across time. Read the transcript here. Simukai Chigudu is Associate Professor of African Politics at the Oxford Department of International Development and Fellow of St Antony's College, Oxford University. He is broadly interested in the politics of global health and epidemics, race and identity, citizenship and activist movements, with a regional focus on Africa and the African diaspora. Simukai is the author of The Political Life of an Epidemic: Cholera, Crisis and Citizenship in Zimbabwe (Cambridge University Press, 2020), an examination of the social and political causes and consequences of Zimbabwe's catastrophic cholera outbreak in 2008/09, the most extensive in African history. This monograph won the Theodore J. Lowi First Book Award from the American and International Political Science Associations. He has conducted research in Zimbabwe, Uganda, The Gambia, and Tanzania, and has publications in several leading social science and medical journals. Simukai has recently published his first book for the trade, Chasing Freedom: Coming of Age at the End of Empire, published by The Bodley Head and Crown in March 2026. This book combines memoir, political history and cultural criticism to show how colonialism continues to shape politics, society and culture in Africa and in Britain and to explore what it really means to decolonise. Prior to working in academia, Simukai was a medical doctor in the UK's National Health Service. He holds a DPhil in International Development from the Oxford University for which he was awarded the biennial Audrey Richards Prize for the best doctoral thesis in African Studies examined at a UK university. Simukai teaches on the MPhil in Development Studies and supervises DPhil students. Ayisha Osori is a lawyer and Director at Open Society Foundations Ideas Workshop. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/biography

"In my home country, they call me a 'bornfree'." Simukai Chigudu was born in Zimbabwe, two years after the end of its bitter war of liberation - a war in which his father had fought. This is the story of his childhood journey through the chaos of that new country's birth to Britain, where he arrived alone, a teenager, burning with ambition but utterly lost in ways he had yet even to discover. Told with astonishing insight, his memoir describes the drama of his quest to belong and to succeed, and how his worldview was both shaped and shattered by Britain, ultimately setting him on a quest to uncover the truth of his parents' past. In excavating their story alongside his own, he brings us closer than ever before to understanding one of the greatest upheavals in modern times - the freeing of a continent from colonial rule - not as history or politics but as a psychological and emotional force, one that divides families from within, even while those same divisions bind them fiercely together across time. Read the transcript here. Simukai Chigudu is Associate Professor of African Politics at the Oxford Department of International Development and Fellow of St Antony's College, Oxford University. He is broadly interested in the politics of global health and epidemics, race and identity, citizenship and activist movements, with a regional focus on Africa and the African diaspora. Simukai is the author of The Political Life of an Epidemic: Cholera, Crisis and Citizenship in Zimbabwe (Cambridge University Press, 2020), an examination of the social and political causes and consequences of Zimbabwe's catastrophic cholera outbreak in 2008/09, the most extensive in African history. This monograph won the Theodore J. Lowi First Book Award from the American and International Political Science Associations. He has conducted research in Zimbabwe, Uganda, The Gambia, and Tanzania, and has publications in several leading social science and medical journals. Simukai has recently published his first book for the trade, Chasing Freedom: Coming of Age at the End of Empire, published by The Bodley Head and Crown in March 2026. This book combines memoir, political history and cultural criticism to show how colonialism continues to shape politics, society and culture in Africa and in Britain and to explore what it really means to decolonise. Prior to working in academia, Simukai was a medical doctor in the UK's National Health Service. He holds a DPhil in International Development from the Oxford University for which he was awarded the biennial Audrey Richards Prize for the best doctoral thesis in African Studies examined at a UK university. Simukai teaches on the MPhil in Development Studies and supervises DPhil students. Ayisha Osori is a lawyer and Director at Open Society Foundations Ideas Workshop. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/politics-and-polemics

"In my home country, they call me a 'bornfree'." Simukai Chigudu was born in Zimbabwe, two years after the end of its bitter war of liberation - a war in which his father had fought. This is the story of his childhood journey through the chaos of that new country's birth to Britain, where he arrived alone, a teenager, burning with ambition but utterly lost in ways he had yet even to discover. Told with astonishing insight, his memoir describes the drama of his quest to belong and to succeed, and how his worldview was both shaped and shattered by Britain, ultimately setting him on a quest to uncover the truth of his parents' past. In excavating their story alongside his own, he brings us closer than ever before to understanding one of the greatest upheavals in modern times - the freeing of a continent from colonial rule - not as history or politics but as a psychological and emotional force, one that divides families from within, even while those same divisions bind them fiercely together across time. Read the transcript here. Simukai Chigudu is Associate Professor of African Politics at the Oxford Department of International Development and Fellow of St Antony's College, Oxford University. He is broadly interested in the politics of global health and epidemics, race and identity, citizenship and activist movements, with a regional focus on Africa and the African diaspora. Simukai is the author of The Political Life of an Epidemic: Cholera, Crisis and Citizenship in Zimbabwe (Cambridge University Press, 2020), an examination of the social and political causes and consequences of Zimbabwe's catastrophic cholera outbreak in 2008/09, the most extensive in African history. This monograph won the Theodore J. Lowi First Book Award from the American and International Political Science Associations. He has conducted research in Zimbabwe, Uganda, The Gambia, and Tanzania, and has publications in several leading social science and medical journals. Simukai has recently published his first book for the trade, Chasing Freedom: Coming of Age at the End of Empire, published by The Bodley Head and Crown in March 2026. This book combines memoir, political history and cultural criticism to show how colonialism continues to shape politics, society and culture in Africa and in Britain and to explore what it really means to decolonise. Prior to working in academia, Simukai was a medical doctor in the UK's National Health Service. He holds a DPhil in International Development from the Oxford University for which he was awarded the biennial Audrey Richards Prize for the best doctoral thesis in African Studies examined at a UK university. Simukai teaches on the MPhil in Development Studies and supervises DPhil students. Ayisha Osori is a lawyer and Director at Open Society Foundations Ideas Workshop. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/british-studies

Two years after researchers identified ReNU syndrome, where are we now?   In 2024, two independent research teams identified the genetic cause of ReNU syndrome, a rare neurodevelopmental condition affecting thousands of people worldwide. The discovery marked the beginning of a new chapter for families searching for answers and opened up exciting new avenues for research.  In this episode, host Sharon Jones revisits the story to explore what has happened since that breakthrough. She is joined by: Professor Nicky Whiffin, Associate Professor and Wellcome Career Development Fellow at Big Data Institute and Centre for Human Genetics, University of Oxford Christina Cox, Co-founder of ReNU Syndrome UK and parent of a child with ReNU syndrome Dr Ana Lisa Tavares, Clinical Lead for Rare Disease at Genomics England Together, they discuss how researchers around the world have built on the original discovery to deepen our understanding of ReNU syndrome, why studying the non-coding regions of our DNA is revealing previously unknown rare conditions, and how collaboration between researchers, clinicians and families is accelerating progress. They also explore how the growing ReNU community is supporting newly diagnosed families and what the future could hold for new treatments.  Links:  Previous episode detailing the discovery of ReNU Syndrome  ReNU Syndrome UK's website  Original research paper from Nicky's team in Oxford  Original research paper from the team based in New York   “It's been only two years since our paper came out about this, and in that time, there are now patient family groups that have been set up all around the world. There is the one in the UK led by Christina and the others. There's the one in the US that's led by a group of four women, and there are ones in France, Spain, like, literally all around the world. And all of these groups are also somewhat coordinated. The leads of these groups meet with each other. They've organised meetups. I've been to ones in the US, the UK, and in France. So the fact that they can mobilise all of that and create such a community so quickly is absolutely incredible.”  You can download the transcript, or read it below. [00:00:00] Sharon: In 2024, two independent research teams identified a genetic cause of a rare neurodevelopmental condition affecting thousands of people around the world. Since then, that initial groundbreaking discovery has grown into something much bigger, bringing together families, researchers, and clinicians, and building a clearer picture of what we now know as ReNU syndrome.  [00:00:26] Sharon: Welcome to Behind the Genes, the podcast that covers everything from cutting-edge research to real-life stories in genomic healthcare. I'm Sharon Jones, and in today's episode, we're looking at what's happened since that discovery, what researchers are continuing to learn, and what the future could hold for people living with  ReNU Syndrome and their families.  [00:00:46] Sharon: To help us understand more, I'm joined by Professor Nicky Whiffin, Christina Cox, and Dr. Ana Lisa Tavares. So, two papers were published around the same time for this condition. To start us off, Nicky, you worked on one of these papers. Could you explain how this journey first began?   [00:01:05] Nicky: Yeah, so this was two years ago now, back in early 2024, where two research teams, so us based in Oxford and a, a group based in New York, were both looking at the data within the National Genomics Research Library, and we both kind of somewhat simultaneously found that there was variance in this very, very small gene, it's called RNU4-2, were found in individuals with previously undiagnosed neurodevelopmental disorders.  [00:01:39] Nicky: And this was very, very striking because we initially actually identified the same single DNA change or mutation in 40 or so different individuals within the National Genomics Research Library, and we normally expect to see a whole host of different variants. We don't expect to see the same one.  [00:01:59] Nicky: So this was a really, really surprising finding. And it was through a collaboration, large scale collaboration across the world where we started contacting our other collaborators who have similar collections of patients who have been genome sequenced to ask if they had any individuals with DNA changes in this gene.  [00:02:17] Nicky: And we found some in the US, some in, in Australia, some in France and Germany. So very, very quickly built up this, this complete picture of variants in this gene, causing this rare neurodevelopmental disorder   [00:02:35] Sharon: of people finding it at the same time, what, what did that feel like?  [00:02:39] Sharon: Like, give us a ense of, like, that compelling, "We think we found something." What was that like?   [00:02:46] Nicky: I didn't believe it initially. You're always told when you're a scientist that if it looks too good to be true, it's, it's not true, and this basically lit up like a beacon. There's this particularly one DNA change that we found in, um, I think it was about 40 different individuals, and we don't really expect that to be the case.  [00:03:04] Nicky: We normally expect these genetic variants to be somewhat randomly distributed across the genome. So to find 40 individuals with exactly the same DNA change was very, very surprising. So initially, I didn't believe it. The whole team, including folks at Genomics England, spent a lot of time trying to check that these variants were real and tried to disprove the result, tried to find any other way in which any other reason why we would be seeing this.  [00:03:31] Nicky: And after a little while, we had to concede that we couldn't disprove it, so it must be true, and that, that was a very exciting moment.   [00:03:38] Sharon Jones: Was it the case that over in the States, the exact same thing was happening?   [00:03:42] Nicky: I think we found out when we were both speaking at the same conference, actually. So we didn't actually know that we, that we'd both come across the same result.  [00:03:49] Sharon: If you want to check out our previous episode on this initial discovery, you'll find a link to it in the episode description.  [00:04:00] Sharon: So Christina, tell us a bit about your situation, your family situation, and for our listeners, what ReNU is.   [00:04:05] Christina: So ReNU is, to us, is a family. We got a family when we got diagnosed with  ReNU. Beau - Arabella - already had other diagnosises, but people had always said to us, "Oh, there's something else. There's something else.  [00:04:20] Christina: We're not sure what it is, but there will be something." And then when we got  ReNU, it was like, "Oh, okay, amazing. What do we do? What is it?" Because there was only four lines on Wikipedia when we first got told about it, and there wasn't anything that, ourselves could find. So we kind of went onto Facebook and looked for groups and different people, and there wasn't really anything except for Jess in America.  [00:04:46] Christina: And then it grew, and then it kind of, we ended up finding more people in the UK and, like, all over. But for us, it didn't really change how we perceived Beau. It just made life easier. Like, knowing there was other families out there that we could find advice from and support from, and that we kind of knew what we had and going forward then, like, finding researchers and connecting with everybody.  [00:05:15] Sharon: Yeah. And for those who don't know, can you talk about what  ReNU is? Like, how does it affect Beau?   [00:05:20] Christina: So with Beau and  ReNU , it affects her with developmental delay. She's non-verbal. She's incontinent. She suffers for walking, so she can do a little bit of walking, but she needs a wheelchair It affects her mood swings.  [00:05:38] Christina: It just affects everything. Although she has it, she's still a happy, outgoing, very stubborn, just kind of "keep-going" child. But it affects her in everything, like eating, sleeping.   [00:05:51] Sharon: It sounds like life is, you know, very challenging on a day-to-day basis, lots of considerations. How did you feel when you finally got this diagnosis after years of wondering and waiting, not knowing?  [00:06:02] Christina: Finding out was, like, really emotional because it was like, "Oh, wow, so we have this diagnosis. Now what? What are we looking for? What's going to happen?" And then we were kind of like, "Oh, but there's not many people that had it." Because we found out in the August, so then it was trying to find people. But it has been life-changing to know that we're not on our own and that there is other people around.  [00:06:28] Sharon: Yeah, tell us a bit more about that. How did it feel to get that diagnosis?   [00:06:32] Christina: It was quite strange because our pediatrician rang us and said, "Oh, we've got a diagnosis. She's got RNU4-2." And we were like, "Okay, so what's that?" And she's like, "I don't really know. There's four lines on Wikipedia at the moment."  [00:06:46] Christina: She goes, "I don't like Wikipedia," but we still kind of... That was it. So then we went on a mission to find and look for where we could find support and find other families.   [00:06:58] Christina: At that point, I didn't know of anybody in the UK, and my husband found Jessica in America. What then, kind of, we had somebody to talk to, and then families in the UK kind of started appearing.  [00:07:09] Christina: So we ended up getting a whole network of people to bounce ideas off and talk about how it affects their children and what's for the future and things like that. It was really nice.   [00:07:22] Sharon: Yeah, yeah, I can imagine. So Ana Lisa, how do these findings contribute to a growing understanding of the condition?  [00:07:29] Ana Lisa: So this was an amazing discovery. Although we're finding new rare conditions quite often, not on this sort of scale. It was also an amazing finding because a lot of the genes that we know are associated with rare conditions are genes that encode proteins, and in the 100,000 Genomes Project, we were doing whole genome sequencing, and Nicky and her team were looking in the parts of the genome that don't encode for proteins.  [00:08:03] Ana Lisa: And so this was, uh, exciting from that point of view as well. So the vast majority of our genome, more than 98%, does not encode for proteins, but it's relatively unexplored. And if we think about our genome and the letter code that makes it up, which is the manual for how our bodies are built, and grow and function day-to-day.  [00:08:30] Ana Lisa: Those 3 billion letters, if you, if you printed them out in a 12 font regular print, it would stretch so far you could fly, I think, from London to Paris several times, maybe three times or something. And so, this actual gene is a very, very small gene, less than 150 of those letters. So again, it was incredible to find that by comparing across many, many different genomes in the National Genomic Research Library.  [00:09:00] Ana Lisa: Going back to your question about a growing understanding of a condition, it was a completely new condition, but it also opened up looking at other related genes and actually now more disorders that are being found, like RNU2-2 by colleagues in the US, and that might be one of the most common recessive genetic neurodevelopmental disorders.  [00:09:27] Ana Lisa: So it's really, really opened up this understanding about these types of disorders and also those non-coding parts of our genome and the power of collaboration and being able to look across many different whole genomes at the same time.   [00:09:44] Sharon: Yeah. And Nicky, you've been involved in much of this research journey.  [00:09:50] Sharon: What have been some of the biggest advances or learnings for you so far?   [00:09:55] Nicky: I think the biggest one is just how common, or how frequent, these disorders are. So what we discovered recently in terms of new genetic disorders were rarer and rarer conditions, and that's why we hadn't seen them before. But from going from looking at the protein coding genes to looking at these non-coding genes, we found something that was as frequent as disorders that were found in the early 2010s when we first had large-scale sequencing projects that looked at the protein coding genes.  [00:10:26] Nicky: So that was really, really surprising. And we now know there's this whole class of disorders. So RN4-2, this gene encodes this -- Well, it produces this small RNA that works in this huge molecular machine that is called the Splicer Zone, that mediates the processing of most of the other genes across the genome.  [00:10:50] Nicky: And there are lots of these little RNAs that work in this molecular machine that are called the small nuclear RNAs or the snRNAs And we now know that there are a whole multitude of different disorders associated with different ones of these spliceosomal small nuclear RNAs, and that's really incredible.  [00:11:09] Nicky: And for RNU4-2 itself, we also now know that there are, there's not just RENE syndrome, uh, which is a dominant disorder caused by chance de novo variants that are newly arisen in a child, but also a recessive disorder where a child inherits one, uh, gene mutation from each parent. And also another finding that there is a region of the gene where we find DNA changes that cause retinitis pigmentosa, so a retinal phenotype. So we now know a huge amount more about this single gene, but also all of this different class of genes or RNAs that work in the same molecular machine, uh, which is, is really fascinating biologically   [00:11:52] Ana Lisa: Vicky, while you were talking, I was thinking about the splicing and how a bit like this podcast recording, you're going to splice out the kind of extreme, the noise that wasn't supposed to be there.  [00:12:03] Ana Lisa: And actually, you could make slightly different versions of this podcast, couldn't you? And that's, that's what, what's happening in our bodies for a lot of our genes that, that the kind of output can be varied slightly.   [00:12:15] Sharon: So Christina, how has collaboration been involved across the community and with researchers?  [00:12:21] Sharon: You know, what sort of things have you been doing?   [00:12:23] Christina Cox: So it's amazing to have researchers that are so open and amazing to work with the families. So at the moment, we are just putting together like a panel to discuss questions from families, to then be able to answer families, to work very closely with the researchers for what things are happening and the progress within.  [00:12:47] Christina: It's just amazing to be able to work with researchers. They're just fantastic.   [00:12:52] Sharon: And from what I understand, like, you, you have a charity, don't you? Can you tell us a bit more about that and how that came about?   [00:12:58] Christina: So we have ReNU Syndrome UK, and it came about as there was a group of us parents that were like, we wanted to be able to support other families, knowing what it was like for us when we first started.  [00:13:12] Christina: It was very difficult. So we wanted to start a charity that can support families and signpost them, give them the opportunity to have family meetups once or twice a year, so we can work with scientists and specialists to keep everybody in the community, like the ReNU family, up to date. But being able to connect with so many families, because a lot of the doctors don't really know of ReNU Syndrome yet.  [00:13:46] Christina: So if we have a problem or a question, we put it in the WhatsApp group, and then somebody can answer it because they've been through it, or they, they've just asked the question. So it's just an amazing resource for everybody   [00:14:02] Sharon Jones: That sounds amazing, and it sounds like you've all obviously become experts by experience.  [00:14:04] Sharon: So, like you say, you kind of know more, you know, as the science develops, but you're living it every single day   [00:14:10] Christina: It's kind of, you go into the hospital and they're like, "Oh, what's ReNU Syndrome?" And then you're like, "Ugh." So, then you just have to say it all. But, and then it's kind of them bringing, teaching new people who don't know about it in the medical professional.  [00:14:26] Christina: We always give them the website so that they can go and then find, but being able to put more medical stuff on the website, it just helps everybody, and it's just broadening it out to as many people as possible. Because there's still a lot of people undiagnosed with RNU syndrome. It's, now it's easier to be signposted, but it's just keeping that connection.  [00:14:49] Sharon: Yeah. And, and from what I understand, it's got quite an interesting sort of origin of a name, RNU. Where did that... Do you know much more about where that came from?   [00:14:57] Christina: So, Nicky is the amazing person who, um, sorted the name and um, the origin. So, I'll pass that over to Nicky to answer that question because she's just amazing   [00:15:11] Nicky: Uh, so the name ReNU syndrome is an interesting story.  [00:15:13] Nicky: So, a lot of disorders or diseases are named after people. So, we all know Alzheimer's, Parkinson's, etc. And they're often scientists or clinicians that have spent a lot of time working on them. I think that's a little bit odd. I don't think it's the first thing that somebody should know about a disorder, is the name of somebody who's, who's worked on it or studied it.  [00:15:36] Nicky: But they're a very, it's very hard to find an alternative. When we were initially doing the press release around our paper, we had a quote from one of the mothers, Nicole Cedar, who has a, a wonderful daughter called Mia Joy, and she said that within their family, they like to refer to RNU, to RNU4-2 as ReNU, which is a really nice play on the RNU in the gene name.  [00:16:00] Nicky: So then I had an idea, okay, let's just change the spelling to make the, the kind of big R, little E, large N-U, then it would link to the gene name, but also would be a name that speaks to hope and the renewed hope of being given a diagnosis.   [00:16:13] Sharon: Yeah, absolutely, and that's a great, a great story and a great way of kind of making it feel like there is, there is always hope.  [00:16:20] Sharon: So, you know, Nicky, you're now part of the patient community. In a way. You know, so how does it feel to be on that other side of it from that sort of research perspective and now kind of, you know, in that, in that community?   [00:16:34] Nicky: It's amazing. I've got a new family as well. It's not, not just Christina and everybody.  [00:16:39] Nicky: I kind of, I'm a, a basic scientist. I'm not a clinician. Up until this point, we've always been one or two steps removed from actually interacting with the families themselves. Um, so my life has changed an awful lot over the last couple of years, uh, where now, um, I kind of talk to Christina or the folks in the US, really regularly, kind of on a weekly basis.  [00:17:02] Nicky: Um, so that's really different. And I just kind of want to highlight just what these families have achieved. So it's been only two years since our paper came out about this, and in that time, there are now patient family groups that have been set up all around the world. There is the one in the UK led by Christina and and the others.  [00:17:26] Nicky: Um, there's the one in the US that's led by a group of four women, and there are ones in France, Spain, like, literally all around the world. And all of these groups are also somewhat coordinated. The leads of these groups meet with each other. They've organised meetups. I've been to ones in the US, the UK, and in France.  [00:17:46] Nicky: So the fact that they can mobilise all of that and create such a community so quickly is absolutely incredible. And they've got families, they've got so many researchers that are interested in the cause. They're interacting with the pharma companies. They've upskilled themselves to learn so much about genetics.  [00:18:04] Nicky: And it's just an absolutely incredible thing to watch. They're so, so inspiring.   [00:18:09] Sharon: And from what I understand, Christina, you feel, you know, very passionate about Nicky in the same way, about your paths crossing in this way.   [00:18:16] Christina: Oh, my, yes. Every time I see Nicky, I've met her a couple of times, like, in person now, I just cry.  [00:18:22] Christina: I literally, we saw her at the UK meetup, and she walked in the door, and that was it. I was done. I was like, it's just meeting somebody who has changed so many lives and brought a community to other families. It's just amazing. And the support that Nicky's giving us weekly, daily, is just amazing. It is just life-changing for all of us.  [00:18:49] Sharon Jones: It's such a powerful connection. So Ana Lisa, why is collaboration between researchers, clinicians, and families so valuable in the rare disease research space? You know, and what role do large scale research projects and data sharing play in discoveries like this?   [00:19:06] Ana Lisa: Collaboration is completely incredibly valuable and for progress in the rare disease space where there's just so much still to learn.  [00:19:16] Ana Lisa: So more than half of patients and families where, uh, they're seeking a potential diagnosis, we're not yet able to, to find one, and there's so much yet that we still need to learn, and collaboration in so many different spaces and directions and across different spheres enables this progress. So for example, the fact that we have a really connected, uh, National Health Service and really close working between the NHS and Genomics England so that we can, for those patients and families that, that consent to their de-identified data being shared in the National Genomic Research Library, be able to work with many, many different researchers, uh, whether they're academic, institutions, industry, and try and find all the patients that could benefit from a new diagnosis and, uh, potentially new therapies in future clinical trials.  [00:20:21] Ana Lisa: And without that collaboration, it would be really, really hard to find all those people So because we sort of have a clinical research interface where we can go back to clinical teams and therefore to patients and families, even if there's a really, really ultra-rare condition with very few people known to have it that could be under different specialties in different regions, we would be able to contact their clinical team.  [00:20:51] Ana Lisa: So I think that, that collaborative working with the NHS is really powerful across researchers worldwide. Like in this example where a group in Oxford and a group in US were able to make this finding and then all the other findings that are coming from it. And really, without being able to compare across thousands of genomes, one wouldn't have been able to see this, this particular signal and see that there were more than 100 patients, and that was really powerful.  [00:21:20] Ana Lisa: If you just had one genome, you could never have made this novel discovery. I think the other thing is that, and Nicky will say that, you know, she, she then contacted her collaborators who also had access to, to, to data that had been shared by other families and could compare. And again, it's a whole sort of network across the globe.  [00:21:41] Ana Lisa: And we know that there are going to be many more diagnoses to be found. But also, um, I think collaboration will allow us to find new, new treatments. So if we can start to design treatments that target the DNA and RNA at, at source, then actually you could collaborate and say, "Well, this type of genetic mechanism could be targeted in the same way, potentially across even more than one rare condition and reach even more patients."  [00:22:13] Ana Lisa: And actually the power of collaboration across the ecosystem is that hopefully we'll end up with a pathway that can actually go from finding a new genetic finding, like Nicky and her team made, to helping all the people who could benefit from a diagnosis, having one, and then can one develop a treatment and get it to as many patients?  [00:22:42] Ana Lisa: And, and I think that will really demonstrate the power of collaboration.   [00:22:47] Sharon: Yeah. Absolutely, and it can only, you know, benefit those families who have to wait such a incredible amount of time.   [00:22:55] Ana Lisa: There's been such a diagnostic odyssey, and as more diagnoses are made, it becomes obvious that there's, uh...  [00:23:03] Ana Lisa: and it was, it's already well-described, the therapeutic odyssey. Um, but hopefully these sort of novel understanding of our genome and opening up new biological avenues to treat, um, hopefully will also enable many more new treatments to be developed.   [00:23:21] Sharon: Absolutely, and that is the key word there is, is that hope.  [00:23:24] Sharon: So, so looking ahead, Nicky, what developments are you most hopeful about over the next few years?   [00:23:31] Nicky: That's a difficult question. There's so much, so much happening. One thing is that we are gearing up to do large scale studies across the world to understand more about the progression of ReNU. So you might call them large scale natural history studies or just large scale profiling studies where we can do a range of different tests on ReNU patients and, and monitor them over time.  [00:24:02] Nicky: So do those at regular, regular intervals over time so we can see what the progression looks like. And that's really important for trying to think about whether we can treat RNeU syndrome. And on that note, I'm very also excited about the potential for therapeutics. There's lots of people all around the world, both, uh, in academic settings, but also in pharma companies trying to work out whether this is something that we can treat.  [00:24:30] Nicky: There's some very promising early data to show that we can selectively remove the RNA containing the mutation from cells, uh, leaving the copy of the RNA that doesn't contain the mutation intact so that can do the correct function. And biologically, we think this should be an effective treatment.  [00:24:54] Nicky: Um, so we can do that in cells in a dish. We don't yet know whether we can do that in a patient with ReNU. Uh, but that's really, really promising early data. Um, so I'm very hopeful about where that, those studies might lead.   [00:25:08] Sharon: And Ana Lisa, what role will genomics continue to play in improving understanding and care for rare conditions like this?  [00:25:15] Ana Lisa: So following on from what Nicky said, I think the really big hope is that we will be able to develop many, many new treatments collaboratively across the world. And whether these are individualised treatments made for one patient but then shared because we can find perhaps other patients who could benefit from the same treatment, whether we understand the genetics better so that we can design treatments from the start that will work for a lot of patients.  [00:25:46] Ana Lisa: So I think there will be sort of fancier and fancier ways of targeting rare conditions. And right now we're in a phase where the ecosystem is trying to work out how could we make an end-to-end pathway with initiatives like the Rare Therapies Launchpad in the UK, and that's going to require truly collaborative working.  [00:26:08] Ana Lisa: No single organisation can do that. And I think having these incredible use cases will be really powerful for turbocharging the development of these pathways. And the hope is that once you've worked out how to do this across a range of different rare conditions, that one might reach a stage where one could do that a lot faster for many other rare conditions.  [00:26:35] Ana Lisa: Because at the moment they're so underserved in terms of treatments available and there's a huge gap between being able to make a genetic diagnosis and then having treatments. The big hope is that understanding the genetics better will help to open up new pathways to treatment. I do hope that we'll also understand other aspects.  [00:27:02] Ana Lisa: So for example, it might be that understanding the genetics better also helps us to understand different ways a condition might manifest in somebody, why it may be different from one person to another, why somebody might be more mildly affected and somebody perhaps more severely. And that might, may also help us to understand ways to treat a condition by getting, gaining these insights which are, are useful in and of themselves and may also lead to new therapeutic, uh, possibilities.  [00:27:36] Ana Lisa: I think that would be one of my hopes that a lot of these areas overlap and lead to real benefit for patients and families, that we can translate that hope into concrete improvements in treatment for rare conditions.  [00:27:57] Sharon: Do you have a sense of time, how long you think this could all take, that amount of collaboration?  [00:28:06] Ana Lisa: Yeah, and I think this is actually another reason why sometimes it's quite tricky to make progress in this area because being able to predict those timelines is notoriously difficult when you look back historically. I'd like to hope that we're on the cusp of having an explosion of novel treatments that can target DNA and RNA, for example, or treatments that target something in the underlying biology that we now understand that we didn't before.  [00:28:34] Ana Lisa: And I do think that there is going to be a big shift. But I think that the sort of confidence intervals around how big that range of time might be is very hard to predict. And that's why I think Christina and Nicky being able to share these stories and about their collaborative working really shines a spotlight on, on what could be done and how progress can happen.  [00:29:02] Ana Lisa: That's really exciting. The other day at a conference, someone from industry stood up and said, "Oh, actually, we set up a clinical trial in the UK because we knew there were patients who could benefit from our work in the National Genomic Research Library," and that was really exciting for us because that's what we want to do; move forwards the opportunities for treatment for patients.  [00:29:28] Sharon: And so finally, Christina, as a parent and member of this community, what are your hopes for the future, and what would you say to families who may still be searching for answers today?   [00:29:39] Christina: It is a long journey, but there is the support and the help out there. If you have any inclination that you think you might have ReNU, reach out to your paediatrician or your doctor to see if you can get your genetic testing done because it's fighting to get the test, to go to people and say, "I think this is what we may have. Can we look into getting it tested?" And reach out to other families and the website and things because it's all about community and supporting and helping people find that diagnosis.   [00:30:16] Sharon: Thank you, Christina, and we'll put the website in the episode description. A huge thank you to Professor Nicky Whiffin, Christina Cox, and Dr. Ana Lisa Tavares for joining me today and sharing their insights and experiences. To learn more about ReNU Syndrome, visit renusyndromeuk.org. If you'd like to hear more stories about the people, research, and discoveries helping to shape the future of healthcare, subscribe to Behind the Genes on your favourite podcast app.  [00:30:45] Sharon: Thank you for listening. I've been your host, Sharon Jones. Behind the Genes is produced by Deanna Barac, Florence Cornish, Sophie McLachlan, and Katie Revell at Bespoken Media. 

Mainstream medicine has a dirty little secret because it routinely fails to diagnose or treat patients who have undergone genuine paranormal encounters. Doctors are trained to look for psychological trauma or physiological disease while completely ignoring the terrifying possibility of external non human manipulation. In this riveting conversation a frontline healthcare veteran lifts the veil on what really happens when the unknown breaches our physical realm.Paul Ascough spent his life serving as a British Army infantry medic and a National Health Service paramedic all while quietly investigating UFO abductions across the United Kingdom. His unique perspective bridges the gap between hard clinical science and the bizarre world of extra dimensional phenomena. Throughout this discussion Ascough details how military cover ups actively suppress public awareness ensuring that vital disclosure never reaches mainstream news outlets.As a veteran BUFORA researcher he shares chilling field accounts from decades of investigating Yorkshire UFO sightings proving that anomalous craft and unexplained entities frequently intrude on unsuspecting civilians.This dialogue forces listeners to confront uncomfortable truths about consciousness and high strangeness challenging the materialistic worldview pushed by modern academia. If you have ever wondered what medical professionals actually witness behind closed doors when reality fractures this interview delivers mind bending answers that will fundamentally shift your perception of existence.✨ Download Our FREE Throne Room Meditation✨ ➡️ https://www.truthseekah.com/throne-room-free➡️ Support on Patreon! https://patreon.com/join/truthseekah✅ Get access to 40+ video lessons + Weekly LIVE calls!✅ Worldwide Online Community!✅ Courses, Monthly Webinars, Prayer, Meditation, Discussion✅ TruthSeekah's Meditation Library

This week on Pulse: Hot Topics, Louise and George look at what happens when digital health stops being a pilot and starts being a system decision — and why, again and again, the technology isn't the hard part.Portugal Buys AI Physiotherapy for an Entire Country — Portugal's National Health Service has contracted Sword Health to make AI-supported physiotherapy available to all 10 million citizens, free after a prescription, prompting the question: are governments shifting from buying AI software to buying AI-delivered healthcare?AI and Accountability: The First Complaints Land — The UK's first complaints about clinicians' inappropriate use of AI have reached professional regulators, arriving well before the evidence base and accountability frameworks are ready.95% of Health Apps Have No Verifiable Regulatory Approval — Rudolf Wagner's analysis found that of nearly 96,000 apps qualifying as Software as a Medical Device, 95% had no verifiable CE marking or FDA authorisation, leaving consumers with no easy way to know what they're actually using.Doctors Want Wearable Data, But Can't Use It — A new AMA(US) survey found 97% of physicians would review data from a patient's wearable, but no more than 6% have actually integrated it, blocked by missing standards, workflow fit, reimbursement and liability.Virtual Care Could Transform Residential Aged Care — Australian researchers found virtual care between aged care homes and GPs improves access and reduces unnecessary hospital visits, but is undermined by poor integration, unreliable networks and limited staff training — the technology works, the system around it doesn't.With Thanks to Datacom:Download the Executive Briefing Playbook LinkResources:Sword Health partners with Portugal's National Health Service LinkFirst complaints made over clinician use of AI, HSJ via Patient Safety Learning Hub LinkEnsuring the clinical impact of medical artificial intelligence, Andreoletti et al., Lancet Digital HealthLinkAnalysis of Software as a Medical Device (SaMD) Compliance in App Store Applications, Rudolf Wagner LinkDocs unable to harness wearables data, survey finds, Axios LinkVirtual care could benefit residential homes – study, Pulse+IT LinkVirtual care in residential aged care homes, Journal of Medical Internet ResearchLinkRecommendations:Clinicians – be part of the research into clinician use of AI, open globally LinkStandards Australia telehealth and virtual care standard LinkThere's An AI For That (TAAFT) newsletter LinkAge-Friendly Futures newsletter, George Gouzounis Link"Welcome to the Land of the Free" — World Cup song by Jason Stills LinkVisit Pulse+IT.news to subscribe to breaking digital news, weekly newsletters and a rich treasure trove of archival material. People in the know, get their news from Pulse+IT – Your leading voice in digital health news.Follow us on LinkedIn Louise | George | Pulse+ITFollow us on BlueSky Louise | George | Pulse+ITSend us your questions pulsepod@pulseit.newsProduction by Octopod Productions | Ivan Juric

Women's Fightback 37, Summer 2026. For centuries medicine had viewed women's bodies as inferior, unstable, weak and dangerous. This legacy still haunts us. As Women's Fightback 37, a Health Special went to press, a damning three-year long review of the biggest childbirth scandal in NHS history concludes revealing brutal treatment of those receiving maternity care. Our editorial charts the history of how women's health has been understood, the role the National Health Service has played in improving women's health and the challenges we face today through inequality, privatisation and distrust in health systems. We have reports of campaigns of workers improving trans healthcare fighting HIV stigma, saving care services and to support sex worker decriminalisation. Our country profile covers women's struggles in Hungary, and we have class struggle feminists reports from Latvia, the US and Nigeria. Articles: Editorial: Women's Health, Inequality and the Future of the NHS Trans Segregation, a New Era of Misogyny: the EHRC Code of Practice Sheffield Trans Healthcare Practice Learning Initiative Fight the EHRC Not Reps! Strike Saves Central Hill Dementia Centre Unionising Against HIV Stigma Challenge to Women's Rights in Latvia Against the Cult of Personality: César Chávez and the UFW Who Cares? UK Fostering System in Crisis Everlasting Bread exposes Nigerian Authorities' Lack of Care for Public Health The Many Lives of Tracey Emin 'Inside the Manosphere' barely scratches the surface Featured Poet: Elly Gault Unions Move to Support Sex Work Decriminalisation Our Family History: a Review of Two Books Obituary: Marjane Satrapi (1969-2026) When Workers Occupied Their Hospital Women's Struggles in Hungary Far right beaten back in Brighton More online: https://workersliberty.org/publications/womens-fightback/womens-fightback-37-summer-2026 Women's Fightback is a socialist feminist magazine by Workers' Liberty. We stand for trans-inclusive, sex-positive, class struggle feminism. We organise in our workplaces and trade unions, and in the student movement and Labour Party for socialist feminist politics. Get your copy now!

In today's Good Morning Portugal news headlines (14 July 2026), AIMA warns foreign residents of document inconsistency delays that can significantly slow residency processing.A judge is investigating alleged financial fraud and executive pay increases within the National Health Service, while the government faces accusations of boosting fuel tax revenues during the Middle East crisis.Emergency services are probing a cardiac arrest response failure in Caldas das Taipas, and a proposed rental law reform has sparked a major political row over tenant protections.Other stories include the Interior Minister under fire after a media exposé, steady banking growth despite lower immigration, stricter citizenship rules now in effect, the NHS purging inactive records, and an investigation into the deeper causes of the Almada water crisis.

In this second sponsored episode with Findmypast — the follow-up to our Genealogy 101 introduction — Jonathan Thomas and Jen Baldwin, Research Specialist at Findmypast, go deeper into the records, techniques, and stories that turn a nervous beginner into a confident family historian. The episode covers the extraordinary richness of the 1921 census and 1939 register, why the newspaper archive is the place where ancestors stop being names and start being people, how the Industrial Revolution left its fingerprints across every family tree, the truth about name changes and spelling variations (it was almost never Ellis Island), how to avoid drowning in common surnames like Thomas or Smith, the unexpected discoveries that make genealogy so addictive — including Jen's own Cornish mail-order bride ancestor, an Irish great-great-grandfather with two arrests across two countries, and Audrey Thompson the World War II rat-catching champion — and how to connect all of it to the great currents of British history. The episode also covers parish records, military records, DNA testing, the role of offline archives, and the mindset that keeps family history a lifelong joy rather than a frustrating quest for perfection. If you haven't heard the first episode, Genealogy 101, go back and listen to that one first. Links Sponsor Findmypast — Start Your Free Trial (US) Findmypast — Start Your Free Trial (UK) British Newspaper Archive (via Findmypast) Findmypast Crime & Criminal Records The Family History Of — Findmypast Podcast Was Justice Served? Podcast — Jen Baldwin Also Referenced Genealogy 101 — Previous Episode with Jen Baldwin (listen first) Friends of Anglotopia Club Takeaways The 1921 census and 1939 register work best as a pair — together they bookend the interwar period, and used in combination they can anchor a family from living memory all the way back through the Victorian era. The 1921 is the most detailed census ever taken in England and Wales; the 1939 register is the only census-style record with full birth dates and tracks maiden-to-married name changes for women. The 1939 register is the foundational document of the NHS — a living document updated for decades after the war, making it uniquely valuable for women's research. ARP warden and Home Guard volunteer roles recorded in its margins bring the home front of World War II vividly to life. Less than 10% of historical records are currently available online. The other 90% live in county record offices, local archives, churches, and museums — and going to them in person, touching the original documents, is an irreplaceable experience that no screen can fully replicate. Names were almost never changed at Ellis Island. Spelling variations in records happen because clerks wrote what they heard, literacy levels were inconsistent, and people adapted their names to the culture they found themselves in. You are researching people, not names — and building a mountain of evidence is the only reliable way to confirm you have the right person. Common surnames are a solvable problem: search by address rather than name, find an unusual first name in the same family, use occupations as a generational signature, and use Findmypast's wildcard and name-variation search tools to cast a wider net before narrowing down. Military records are one of the most common gateways to unexpected discovery — attestation papers, service records, pension files, and medal rolls fill in the specifics of what an ancestor actually did, where they served, and what happened to them. The Pals battalions of World War I, where entire communities enlisted together and died together, are particularly powerful to research. Parish records predate civil registration by centuries — the earliest on Findmypast go back to the 1300s — and the parish chest records that accompany them reveal an ancestor's role in their community: tax records, poor relief, bastardy orders, apprenticeship documents, and more that have nothing to do with baptism but everything to do with understanding a life. DNA testing adds a powerful new dimension to family research — not as a replacement for documentary evidence, but as a corroborating tool that can confirm suspected connections, break through brick walls by connecting you to unknown cousins, and reveal migration patterns that the paper records haven't caught yet. The best cure for a genealogy brick wall is to switch branches entirely. Fresh eyes on a different part of the family tree — maternal lines, in-laws, siblings — often reveals the clue that unlocks the original problem. The answer to who your Thomas ancestor was is sometimes hiding in his wife's maiden name records. Replace the goal of a perfect family tree with the practice of curiosity. The satisfaction of genealogy is not in the quantity of ancestors collected but in the two-in-the-morning moment when everything suddenly clicks — and that moment always opens a hundred new questions. This is a lifelong hobby, and patience rewards it far more than brilliance does. Soundbites "She answers a mail order bride ad in Cornwall. She travels by herself across the Atlantic, gets on a train, goes to the highest incorporated town in Colorado at ten thousand feet, marries this man sight unseen. He dies in a mining accident. She waits a few months, answers another ad, gets on another train with her kids, moves to Nebraska. They shake hands, go to the courthouse, get married. That's not as unusual as you might think." — Jen on her Cornish ancestor Mary Daniels and the extraordinary ordinary lives migration records reveal. "Their name was not changed at Ellis Island. Did it happen occasionally? Yes. But not because someone at a table said, I think you look more like a Smith. Names change because clerks wrote what they heard. You are researching people, not names." — Jen on the biggest myth in genealogy. "I found a gentleman who fills the census in black ink — except for the marriage column, which is a giant red D that he has clearly spent a lot of time on. It's written over and over. You can see the imprint on the page. He felt very passionately about his divorce." — Jen on the 1921 census entry that is worth the price of a subscription on its own. "She volunteers for the Women's Land Army and the next thing you know she is the country's top rat catcher. She enters the competition, travels the country giving presentations, getting her picture taken by local media — the top rat catcher fighting to save Britain from the Nazis. Because we needed the crops." — Jen on Audrey Thompson, one of her favorite unexpected discoveries. "He gets arrested twice. Once in Ireland and once in Wales — the situation in Wales was a bar fight, quite literally, covered in the newspaper in a lot of detail. He ends up in Cork prison, then Wales, then Liverpool, then Pennsylvania. I know all of that because of newspapers, arrest records, and a passenger list. The records all connect to tell a much deeper story." — Jen on tracing an Irish ancestor through famine, crime, and migration. "There's only about a percent of historical materials actually available online. There are more records sitting in archives and churches and museums and little nuggets all over the country. Go to the county records office. Go to the cemetery. Touch grass. Actually get away from the screen — because it connects you with the past in a way you could never duplicate in an online experience." — Jen on why physical archives still matter. "The 1939 register is the foundational records for the National Health Service. It was a living document for decades after the war. When women got married from 1939 on, you have their maiden name recorded and then they would go in and scratch out the maiden name and write their married name over the top. For women's research, it's particularly important." — Jen on why the 1939 register is so valuable. "I went to the church in St. Dunstan's Parish in the East. They still have the same baptismal font sitting in the building. And the steps down to the Thames along Radcliffe Highway are still in the same place as they were in the 1600s when my ancestors would have been there. I believe I'm the first person in our direct line to go back to London since they left in 1635. That first trip over was extraordinarily special." — Jen on the moment family history becomes real. "In a Pals battalion, they recruited whole battalions from the same community. All those men were neighbors before the war. They went to school together, they married each other's sisters, they went to church together. You get this situation where you're looking at an entire village of people who enlist and then get caught up in a battle and hundreds of them die in the same night. This is more than just a pedigree chart. This is an opportunity to remember them." — Jen on World War I Pals battalions and why war memorials matter. "You make a discovery and you've been researching this for hours or sometimes months or years, and you finally find it. It's two o'clock in the morning and you are literally jumping up and down in front of your computer. And then you realize I found this thing — but now I have a hundred more questions. That's the bit that keeps people coming back." — Jen on the true nature of the genealogy addiction. Chapters 00:00 Introduction & Sponsor Message — Findmypast and the Genealogy 201 premise 02:07 Picking Up Where We Left Off — A recap of Genealogy 101 and the call to action 02:32 The 1921 Census and 1939 Register as a Pair — Bookending the interwar period 03:30 What Makes the 1921 Census So Special — Employer names, divorce, orphan data, and handwriting 03:37 The Man with the Giant Red D — A census entry that tells an entire emotional story 05:00 The 1939 Register — ARP wardens, full birth dates, maiden names, and the NHS connection 07:42 Why Was There No 1931 or 1941 Census? — A brief recap for new listeners 08:51 What the 1939 Register Tells Us That a Census Can't — Women's names, volunteer war roles, and evacuated children 10:06 Newspapers as the Place Where Ancestors Come Alive — The 19th-century explosion and what it captured 11:30 The Three Brothers and Their Mother — A World War I story told entirely through local newspapers 12:45 The Industrial Revolution and Migration — Following opportunity from countryside to city to colony 13:30 Mary Daniels from Cornwall — A mail order bride, Colorado, a mining accident, Nebraska, and the homestead that's still in the family 17:09 Why Ancestors Move Around — Following jobs, the 20-mile radius rule, and how records help you track them 19:38 What Findmypast Offers Beyond the Census — Partnerships, niche collections, and British-based expertise 21:00 Metropolitan Police Records, Parish Records, and the Federation of Family History Societies 21:53 The National Archives Partnership — Military records, crime records, and the Licenses to Pass Beyond the Seas 23:40 Jen's Own Ancestor in the 1635 Passenger List — Henry Collins, three children, four servants, and a socioeconomic revelation 24:55 Not Everything Is Online — Less than 10% of records are digitized; why you should still visit archives 26:58 Even the Emperor of Japan Uses Archives — A digression on Oxford, shipping records, and the world's most patient researcher 28:24 Name Changes and Spelling Variations — Why Ellis Island didn't do it and what actually happened 28:58 The Jacobs/Jacobich Problem — And Jen's own family dropping the E off Browne 31:43 You Are Researching People, Not Names — Common sense is queen 32:29 Findmypast's Name Variation Search and Wildcard Tool — How to cast a wider net 33:37 Dealing with Common Surnames — Occupations, addresses, unusual first names, and process of elimination 35:30 Suddenly Grateful for Abel — Jonathan's uncommon grandfather and why unusual names are genealogical gold 35:48 Unexpected Discoveries That Make It All Feel Alive — Military service, migration stories, and the records that connect 36:02 A Famine Survivor, Two Arrests, and a Bar Fight in Wales — Jen's Irish ancestor's journey 37:56 Audrey Thompson, Top Rat Catcher — How the Women's Land Army and newspaper archive combine 39:00 True Crime in the Records — A domestic servant, a storm, an affair caught in a parish church, and the real-life whodunit 40:50 British Remembrance vs. American Remembrance — Plaques in banks, poppies, and why the UK doesn't forget 42:17 Findmypast's War Memorial Collection — Photographed memorials with every name listed, accessible from Colorado 44:00 The Pals Battalions — Entire villages enlisting, fighting, and dying together in World War I 45:22 Visit War Memorials When You Travel — What they tell you about a village's past and the state of its memory 45:30 Perfectionism vs. Curiosity — Why the chase is better than the finish line 47:24 Up at Two in the Morning — The two o'clock discovery and the hundred questions it opens 48:02 When People Don't Find the Castle They Expected — Why your ordinary ancestors are more interesting than any aristocrat 49:38 Three Assignments for After This Episode — Parish records, switching branches, and citing your sources 49:59 Parish Records Explained — Baptism vs. birth, burial vs. death, parish chest records, and the records from the 1300s 53:31 Why Switching Branches Solves Problems — Fresh eyes, new records, and how the puzzle connects 55:27 Why Citing Your Sources Matters — Future you will forget, and Findmypast Workspaces can help 57:46 The Mindset That Turns a Beginner Into a Historian — Replace perfection with curiosity, embrace the lifelong hobby 59:09 Jen's Own Family Tree Back to 1635 — St. Dunstan's Parish, Radcliffe Highway, the baptismal font, and being the first to return 1:00:41 Jonathan's Takeaway — Time to call grandma and fill in the family tree 1:01:54 Wrap-Up and Sponsor Outro — Findmypast free trial links and an invitation to share discoveries Video Version

We've talked a lot on this podcast about institutional capture — whistleblowers, mission drift, what happens when ideology takes the steering wheel. Today my guest takes a different angle on all of it.Tanya de Grunwald hosts This Isn't Working, a podcast about workplace dynamics, and runs This Is Working, a business community for employers. From 2018 to 2024 she ran a club for early-careers heads at companies like Google, KPMG, AstraZeneca, and the NHS — a front-row seat to peak DEI from the inside. By 2024 she'd seen enough unintended consequences, especially around the trans agenda, to walk away and start telling the story.In this conversation we trace the personal psychology underneath workplace wokeness: the embarrassment about capitalism that pushed HR toward "higher purpose," the older gay men reliving Section 28 through trans activism, the weaponized fragility that lets the loudest voice win every argument. Tanya explains the brain drain that happens when sensible people leave and "nodding dogs" stay behind — and why the private sector is now leading the cleanup.We also dig into what bullied kids fail to learn about self-protection, why "bring your whole self to work" is a mental-health disaster, and what it looks like when leaders finally take the room back. If you've been wondering whether the vibe shift is real, this episode is your field report from someone who sees the spreadsheets.Tanya de Grunwald hosts This Isn't Working, a podcast exploring what has gone wrong in modern workplaces. In 2010 - after 10 years as a features writer for Glamour, Cosmopolitan and the Guardian - Tanya founded the careers blog Graduate Fog, and became a youth recruitment strategist. From 2018-24, Tanya ran the Good + Fair Employers Club, helping big UK employers including Google, KPMG, AstraZeneca and the National Health Service to hire graduates and apprentices. Last year, Tanya founded the business network This Is Working, bringing sensible employers together to unpick their problems. She is regularly quoted in UK newspapers including the Daily Telegraph and the Daily Mail. Follow her on X @IsntWorkingPod or YouTube ⁨@This-Isnt-Working⁩ [00:00:00] Start[00:02:34] Workplace Dysfunction and the DEI Agenda[00:05:54] Inside the Peak DEI Years[00:11:23] Embarrassment About Capitalism[00:15:00] Older Gay Men and Workplace Activism[00:19:00] Weaponized Fragility in Arguments[00:29:04] Self-ID Confusion and Legal Risk[00:30:45] The Corporate Brain Drain[00:35:47] Affirming Parents in Senior Leadership[00:41:54] The Piggy Lesson on Bullying[00:52:55] The Workplace as Cultural Collision Point[01:00:32] Comfort, Challenge, and Young Workers[01:06:52] The Vibe Shift and the Private Sector[01:16:12] Bring Your Professional Self to Work[01:24:47] We Make PaperclipsROGD REPAIR Course + Community gives concerned parents instant access to over 120 lessons providing the psychological insights and communication tools you need to get through to your kid. Now featuring 24/7 personalized AI support implementing the tools with RepairBot! Use code SOMETHERAPIST2026 to take 50% off your first month.PODCOURSES: use code SOMETHERAPIST at LisaMustard.com/PodCoursesPRODUCTION: Looking for your own podcast producer? Visit PodsByNick.com and mention my podcast for 20% off your initial services.MUSIC: Thanks to Joey Pecoraro for our song, “Half Awake,” used with gratitude & permission. ALL OTHER LINKS HERE. To support this show, please leave a rating & review on Apple, Spotify, or wherever you get your podcasts. Subscribe, like, comment & share via my YouTube channel. Or recommend this to a friend!Learn more about Do No Harm.Take $200 off your EightSleep Pod Pro Cover with code SOMETHERAPIST at EightSleep.com.Take 20% off all superfood beverages with code SOMETHERAPIST at Organifi.Check out my shop for book recommendations + wellness products.Show notes & transcript provided with the help of SwellAI.Special thanks to Joey Pecoraro for our theme song, “Half Awake,” used with gratitude and permission.Watch NO WAY BACK: The Reality of Gender-Affirming Care (our medical ethics documentary, formerly known as Affirmation Generation). Stream the film or purchase a DVD. Use code SOMETHERAPIST to take 20% off your order. Follow us on X @2022affirmation or Instagram at @affirmationgeneration.Have a question for me? Looking to go deeper and discuss these ideas with other listeners? Join my Locals community! Members get to ask questions I will respond to in exclusive, members-only livestreams, post questions for upcoming guests to answer, plus other perks TBD. ★ Support this podcast on Patreon ★

Katie Brennan's experience with Long COVID began in the earliest days of the pandemic, while she was working with the UK's National Health Service on data-driven policy changes to improve care for patients. Though her experience with the acute phase was relatively minor, instead of steadily recovering, she developed a range of ongoing symptoms—difficulty breathing, sudden heart rate spikes, dilated pupils, fatigue, brain fog, and difficulty focusing. Although she was still functional enough to work, everything felt harder, and she no longer felt like herself. Eventually, she realized she had Long COVID. Navigating the push–crash cycle is common for many people with chronic illness: Katie would push herself too hard, frustrated by what her body could no longer handle, then crash and face hours or days of exhaustion and other symptoms as she recovered. A second COVID infection eroded what gains she had made. Recognizing the need to try something new, Katie attended a fitness class run by former biathlon Olympian and world champion Andrea Henkel Burke. Andrea's combination of gentle but purposeful movement and various nervous system regulation techniques gave her participants small, tangible ways to control the body's shift out of near-constant fight-or-flight into essential rest-and-repair.   Together, Katie and Andrea founded ThriveNinety, which aids people with Long COVID and other infection-induced conditions by translating science into simple, practical tools that help restore how their bodies function and help them rebuild capacity and performance. Their program provides movement and other sensory inputs that are accessible for anyone, wherever they're at in their illness recovery or maintenance. They also guide participants through nutritional changes known to have a positive effect, such as anti-inflammatory diets. Throughout her journey, Katie has discovered the phenomenal impact of listening to her body's cues and making proactive adjustments that enable her to live a healthy, happy, active life with Long COVID. ThriveNinety shows others how they, too, can improve and even thrive in the face of long-term illness. Learn more about ThriveNinety's programs and mission: https://www.thriveninety.com/  Buy the book, Recovery Kitchen: https://www.thriveninety.com/recovery-kitchen PlayWatch the episode on YouTube or Spotify, listen here on our website or on your favorite podcast platform. PODCAST LINKSWEBSITE: https://majorpainpodcast.comEMAIL: majorpainpodcast@gmail.comSUBSCRIBE: https://majorpainpodcast.com/subscribeSPOTIFY: https://open.spotify.com/show/5NDoD07WJmICdfdRKq0TyNAPPLE PODCASTS: https://podcasts.apple.com/us/podcast/major-pain/id1562947550?mt=2&ls=1 SOCIAL MEDIAINSTAGRAM: https://www.instagram.com/majorpainpodcastTIKTOK: https://www.tiktok.com/@majorpainpodcastYOUTUBE: https://www.youtube.com/@MajorPainPodcastFACEBOOK: https://www.facebook.com/majorpainpodcast AFFILIATE LINKSRARE PATIENT VOICE: https://rarepatientvoice.com/MajorPainPodcastAMAZON SHOP: https://www.amazon.com/shop/majorpainpodcastNEURAHEALTH: https://www.neurahealth.co/majorpain

Ten years on, the UK's decision to leave the European Union is increasingly seen as more than a single referendum result. Critics argue it reflected a wider crisis of political imagination, with Brexit supporters misreading both Britain and the world, while the promised future never arrived. The referendum held on 23 June 2016 remains one of the defining decisions in modern British history. Supporters promised sovereignty, control, lower red tape, new trade deals and a more dynamic “Global Britain”. Critics are unequivocal that Brexit has left Britain poorer, weaker and less able to deal with global shocks 10 years after voters chose to leave the European Union. Opponents argue that many of those promises have not been met. Britain is more constrained, less attractive to investors and still divided over what Brexit was supposed to mean. Nevertheless, the vote marked the moment Britain “changed track”, Colin Hay, professor of political science at Sciences Po in Paris, tells RFI. “Its relationship with the European Union and its relationship with the rest of the world has changed fundamentally from this moment onwards,” Hay said. “And 10 years on, we can see that very clearly now.” Two years after Brexit 'got done', poll shows many Britons want new referendum A changed Britain Brexit is hard to judge as a normal policy decision, Hay argues, because voters were asked to choose a direction without knowing what form leaving the EU would eventually take. “People didn't know what the Brexit that they were voting for, if they voted for it, would turn out to be, and now they can see, and there's a certain amount of buyer's remorse, I think,” Hay says. One of the strongest attacks on Brexit has come recently from Michael Heseltine, the former Conservative deputy prime minister, who called it a “self-imposed disaster” and a “con”. He also said those who sold it should “hang their heads in shame”. For Hay, Heseltine was pointing to a real problem in British politics – especially the way Europe moved from a low-profile issue to the central question shaping political life. “The question of Britain's relationship to Europe was – until UKIP came along and until the Brexit referendum – a relatively low salience issue,” Hay said. “Since 2016 and since the campaign, it has been the single dominant issue, which has influenced everything else.” That change helped Nigel Farage, UKIP and later Reform UK become powerful forces in British politics, while also damaging the Conservative Party. 'Rogue state' UK stands by new Brexit legislation which breaks international law Economic costs The economic impact of UK's departure from the European Union is now clearer than it was at the time of the referendum, Hay tells RFI, though he adds that Brexit cannot be separated entirely from the other shocks Britain has faced over the past 10 years. “I think it's as clear as it could be, but there's a caveat in that, and that is that a lot's happened in Britain over the last 10 years, lots happened in the world over the last 10 years, and to identify and to isolate the Brexit effect is actually quite tricky,” he says. The Bank of England has tried to measure the impact, estimating “a drop of 6 percent of GDP lost, as it were, to Brexit”. But the wider cost may be greater because Brexit also affected Britain's ability to deal with later crises, including Covid and the Ukraine war, he argues. Five years on, has Brexit put Britain at a disadvantage in EU talks? “Britain is less well placed to deal with those shocks and challenges today than it would otherwise have been in the absence of Brexit,” Hay continues. The idea of a newly liberated “Global Britain” was always weak, because the UK already had many favourable trade terms through its EU membership. “I think the idea of a kind of new ‘Global Britain' liberated from Europe was always a bit of a myth, frankly,” Hay says. The promise of “Singapore-on-Thames” also failed to deliver. Britain was already a relatively lightly regulated European economy and had long been highly deregulated in financial services. “There's been a marginal move in the direction of light regulation, but it's not really achieved any positive gain for the British economy overall,” Hay said. Countdown to Brexit: Polls predict Leave campaign wins Campaign arguments However, the Leave campaign was highly effective in attacking warnings from economists, diplomats, businesses and officials with “Project Fear”. That tactic weakened the role of evidence in the debate, while the Leave side also used the promise that Brexit would free up money for the National Health Service. “I think the Brexit campaign was most effective in a sense, because it was able to discredit and disable any evidence, any expertise that was brought on the remain side of the debate to the table,” Hay says. The campaign, led in part by Farage and his populist message, encouraged voters to reject not only the EU but also “the form of expert technocratic governance associated with that”, he argues. At the same time, Leave campaigners used a simple financial promise. “They plastered a big number on big red buses and implied that a vote for Brexit would liberate the public finances and allow high levels of investment in the NHS, amongst other things,” Hay says. The result did not match that promise, he adds. EU and UK clash in first post-Brexit legal battle over North Sea fishing ban “Anyone who's tried to be treated in a British hospital in the 10 years since 2016 knows that that didn't turn out very well,” Hay says. Brexit supporters often argue that the vote was not mainly about economics but about sovereignty and control. Farage and others have also claimed that Brexit failed because it was never properly implemented. Hay explains that argument was easy to make and had been repeated since Theresa May's time as prime minister, when she faced pressure to deliver a harder and more economically costly form of Brexit. But public opinion has shifted over the past decade. “I think the argument that Brexit was not properly implemented, and that's why it's not turned out as well as it could have done, has not particularly been accepted by the public,” says Hay. Around 20 to 30 percent of those who voted for Brexit would now vote remain if given the chance again, he estimates. Burnham wins key UK poll, paving way for bid to challenge PM Starmer Uncertain future Meanwhile, Keir Starmer's government has been trying to rebuild bridges with the EU while avoiding a return to the divisions of the Brexit years. The debate inside Labour is also becoming more complex, with questions over how far any future leader could go in rebuilding Britain's relationship with the EU. For Hay, Britain's uncertainty 10 years after Brexit is closely tied to economic weakness. “It's much easier to be confident about Britain if it has a stronger economy,” he says. “The Labour administration assumed it would have more fiscal space to do positive things every single time it looks at the books,” Hay said. “It finds there's no money in the coffer, and if there's no money in the coffer there's not much you can do.” Ten years after the vote, Brexit remains more than a question of treaties, borders and trade. It is also a question of what Britain was promised, what was delivered and how much control the country really gained.

-Wired uncovered the dormant tool that contained algorithms which would have converted photos of faces into biometric identifiers stored on-device and cross referenced with each new facial scan. -Meta is once again asking a court to intervene in its long-running battle against spyware maker NSO Group. -The UK government is reviewing its National Health Service partnership with US data firm Palantir to decide if it will end the contract early. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In Singapore, a group of runners charge 50p per kilometre to run on strangers' Strava accounts.  That's how far people will go to look fit online.  This episode explains the psychology behind why being watched changes everything. --- Owain's book: https://amzn.to/4smVtrP  Owain's company CogCo: https://cogco.co/  Unlock the Nudge Vaults: ⁠https://www.nudgepodcast.com/vaults⁠  Join 11,626 readers of my newsletter: ⁠https://www.nudgepodcast.com/mailing-list ⁠ Connect on LinkedIn: ⁠https://www.linkedin.com/in/phill-agnew/⁠ --- Today's sources:  Gerber, A. S., Green, D. P., & Larimer, C. W. (2008). Social pressure and voter turnout: Evidence from a large-scale field experiment. American Political Science Review, 102(1), 33–48. Sallis, A., Harper, H., & Sanders, M. (2018). Effect of persuasive messages on National Health Service organ donor registrations: A pragmatic quasi-randomised controlled trial with one million UK road taxpayers. Trials, 19, 513. Service, O., & Gallagher, R. (2017). Think small: The surprisingly simple ways to reach big goals. Michael O'Mara Books.Triplett, N. (1898). The dynamogenic factors in pacemaking and competition. American Journal of Psychology, 9, 507–533.

In this thought-provoking episode, host Gabe Howard sits down with child psychiatrist and author Dr. Sami Timimi to challenge some of the most widely accepted ideas in modern mental health care. Drawing from his latest book, “Searching for Normal: A New Approach to Understanding Mental Health, Distress, and Neurodiversity,” Dr. Timimi explores why diagnoses like ADHD, depression, and anxiety may be less about biology and more about cultural context. The conversation dives into how labeling distress can sometimes obscure the real drivers of human experience—life experiences, relationships, and environments. Listeners will learn: the risks of viewing mental health challenges as lifelong disorders how context, development, and adversity shape emotional experiences what a more humane, supportive approach to distress could look like This episode invites listeners to reconsider what it means to be “normal,” and whether our current mental health framework is helping — or limiting — our understanding of the human condition. If you've ever questioned the labels, wondered about overdiagnosis, or wanted a deeper conversation about mental health beyond the surface, this episode is for you. “We have this fantasy that we can live lives that are devoid of any sort of emotional suffering, but that creates a really artificial idea about what life should be like." ~Dr. Sami Timimi, author of Searching for Normal Our guest, Dr. Sami Timimi, is a practicing consultant child and adolescent psychiatrist and psychotherapist in the UK's National Health Service. He has contributed to over forty books on subjects related to critical psychiatry, childhood, psychotherapy, depression, behavioral problems, and cross-cultural psychiatry; authored six books, including “Naughty Boys: Anti-Social Behaviour, ADHD, and the Role of Culture” and “Insane Medicine: How the Mental Health Industry Creates Damaging Treatment Traps and How You Can Escape Them”; co-edited four books, including “Liberatory Psychiatry: Philosophy, Politics and Mental Health with Carl Cohen”; and co-authored two others, including “The Myth of Autism: Medicalising Men's and Boys' Social and Emotional Competence” with Neil Gardiner and Brian McCabe. His most recent book is “Searching for Normal: A New Approach to Understanding Mental Health, Distress and Neurodiversity.” Our host, Gabe Howard, is an award-winning writer and speaker who lives with bipolar disorder. He is the author of the popular book, "Mental Illness is an Asshole and other Observations," available from Amazon; signed copies are also available directly from the author. Gabe is also the host of the "Inside Bipolar" podcast with Dr. Nicole Washington. Gabe makes his home in the suburbs of Columbus, Ohio. He lives with his supportive wife, Kendall, and a Miniature Schnauzer dog that he never wanted, but now can't imagine life without. To book Gabe for your next event or learn more about him, please visit gabehoward.com. Please share the show with everyone you know! Learn more about your ad choices. Visit megaphone.fm/adchoices

On this new episode of THE POLITICRAT daily podcast Omar Moore plays the audio of the entire May 5, 2026 CNN California governor candidates' debate in Monterey Park, California. And a correction: Nye Bevan, not Nan Bevan, as Omar incorrectly stated in this episode, was the architect of the National Health Service in the UK.WARNING: This episode contains foul language. Listener discretion is advised.Recorded May 6, 2026.Subscribe on Substack: https://popcornreel.substack.comSubscribe on YouTube: https://youtube.com/@thepoliticratpodBUY MERCH FROM THE POLITICRAT STORE:https://the-politicrat.myshopify.comBUY BLACK!Patronize Black-owned businesses on Roland Martin's Black Star Network: https://shopblackstarnetwork.comBLACK-OWNED MEDIA MATTERS:(Watch Roland Martin Unfiltered daily M-F 6-8pm Eastern)https://youtube.com/rolandsmartin

Send us Fan MailIn this episode of Privacy Please, Cameron Ivey investigates Palantir Technologies — a data analytics company founded in 2003 with CIA backing that has quietly become embedded across nearly every major arm of the U.S. federal government.This week's investigation covers:The USDA Deal On April 22nd, the Department of Agriculture signed a $300 million blanket purchase agreement with Palantir to build "One Farmer, One File" — a unified digital profile for every American farmer. The deal was awarded without competitive bidding.The IRS Bombshell The same week, The Intercept revealed — based on documents obtained by watchdog group American Oversight — that Palantir has been running financial crime surveillance operations inside the IRS since 2018. The IRS has paid Palantir over $130 million for access to a platform that cross-references bank records, tax filings, transaction histories, and more across millions of Americans.The Immigration Enforcement Machine Palantir's ICE contracts — now over $145 million — power the agency's case management, deportation targeting, and real-time location tracking of immigrants. A tool called ELITE creates individual dossiers on deportation targets by pulling data from the Department of Health and Human Services.The Pushback That's Working New York City's public hospital network canceled its Palantir contract after community organizing and City Council pressure. In the UK, 229,000 people have signed petitions to remove Palantir from the National Health Service. Public pressure is moving the needle.Five Things You Can Do Right Now Cameron closes with specific, actionable steps every listener can take — from requesting your IRS transcript to freezing your credit to contacting your representative about sole-source contracting.Privacy Please is part of the Problem Lounge Network. New episodes weekly. theproblemlounge.comChapter Markers 00:00 — Cold Open01:30 — Intro & Show Welcome02:45 — Act One: The USDA Deal06:00 — Act Two: Who Is Palantir?11:30 — Act Three: The Empire Expands (ICE, Policing)17:00 — Act Four: Your Tax Returns Are In There Too24:00 — Act Five: The Layer Nobody's Talking About30:00 — Act Six: The Part That Gives Me Hope34:30 — What You Can Actually Do (5 Tips)39:00 — Closing Reflection (Adjust timestamps after editing)Support the show

DW's Lars Bevanger reports on a new a controversial contract between Britain's National Health Service and the US data and spy tech company Palantir. The post Increasing frustration over UK deal with spy tech company appeared first on The World from PRX.

DW's Lars Bevanger reports on a new a controversial contract between Britain's National Health Service and the US data and spy tech company Palantir. The post Increasing frustration over UK deal with spy tech company appeared first on The World from PRX.

President Donald Trump has struck a deal with the UK that exempts prescription drugs imported to the United States from tariffs for three years. In exchange, Britain’s National Health Service will pay 25% more for new drugs. The question now is: Can the U.S. negotiate similar deals with other countries? In this week’s episode of "The Top Line," we examine the drug pricing agreement between the UK and the U.S. Fierce Pharma’s Kevin Dunleavy explores the issue with Jeffrey Gerrish, who served as deputy U.S. trade representative for Asia, Europe and the Middle East during the first Trump administration. They break down the specifics of the UK-U.S. partnership and whether the deal could be applied to other countries to bring drug prices more in line with those in the U.S. They also discuss Trump’s other attempts to use America’s economic power to secure drug pricing agreements. To learn more about the topics in this episode: UK signs off on US pharma deal, ensuring tariff reprieve as Britain aims to reattract investments Merck executes its own Brexit, moving all R&D operations out of UK AstraZeneca's Soriot is considering move of stock listing to the US: Times See omnystudio.com/listener for privacy information.

A transgender doctor at the centre of a costly legal battle in the UK has been registered as female by Australia’s medical regulator. Plus, Xi Jinping calls for passage through Strait of Hormuz to be restored and Tim Cook to step down as Apple CEO. Read more: Trans doctor Beth Upton at centre of UK dispute now working in Australia China's Xi calls for normal Hormuz passage Vance set to depart for talks as Iranians stall: report Apple hardware executive John Ternus to become CEO after Tim Cook steps downSee omnystudio.com/listener for privacy information.

In this gentle and deeply grounding episode, Gabby talks to psychiatrist, psychotherapist, and bestselling author Sue Stuart‑Smith to explore the profound connection between gardening, nature, and our mental wellbeing. Drawing on her acclaimed book "The Well Gardened Mind", Sue reflects on her journey from clinical psychiatry into the therapeutic world of gardening, sharing powerful stories of people who have found healing, resilience, and renewed purpose through tending to plants. Together, Gabby and Sue delve into the emotional and psychological benefits of reconnecting with the natural world. They discuss how gardening can soothe the nervous system, why sensory experiences in nature offer such deep comfort, and how even the smallest moments of green space can help us feel more regulated and grounded. Sue explains the symbolism and emotional power of flowers, the importance of community gardens in fostering connection, and the impact that modern screen culture and urban living have on our mental health. This conversation isn't about being a “good” gardener or having a perfect green thumb. It's about remembering our innate relationship with nature and recognising that nurturing something living - even a single plant on a windowsill - can quietly nurture us in return. As Sue beautifully says, “When we work with nature outside us, we work with nature inside us.” Whether you're an experienced gardener or someone who has never planted a seed, this episode offers a calming reminder that nature is always available to support us. It's a conversation about what it means to be human, to be rooted, and to rediscover the grounding power of the natural world. Sue Stuart‑Smith is a psychiatrist, psychotherapist and the author of The Well Gardened Mind, a Sunday Times Bestseller that was named one of The Times' 37 best books of 2020 and awarded Gardening Book of the Year by The Sunday Times. She originally studied English Literature at the University of Cambridge before qualifying as a doctor and spending many years working in the National Health Service, where she became the lead clinician for psychotherapy in Hertfordshire. Sue now teaches at the Tavistock and Portman NHS Foundation Trust in London and works as a consultant at DocHealth, a not‑for‑profit psychotherapeutic consultation service for doctors. ​​To download the free My Possible Self App: https://mypossibleself.app.link/podcast To follow My Possible Self on Instagram: https://www.instagram.com/mypossibleself/ For more on Sue, her projects and book: https://www.suestuartsmith.com/ To follow Sue on Instagram:   https://www.instagram.com/suestuartsmith  

Good morning. The strike by resident doctors highlights the severe tensions faced by the National Health Service. The tragedy of the dispute, and any disruption experienced by patients, is that all sides involved no doubt very much want health services to improve. So as resolution is sought can this also be a moment to ask again an increasingly pressing question. What exactly is health? The issue often came to the fore when I worked in the NHS. My role was as a psychotherapist in a psychiatric hospital. We worked with older adults who had often suffered for not just years but decades. Their pain was substantial and entrenched. What could be offered to such folk? What did we mental health professionals think we were doing? There were no easy answers. Suffering is hard. But a light might flicker in the darkness when a patient felt heard. They realised, even momentarily, that they were with someone who didn't have any immediate remedy but did appreciate the depth of their torment. Many doctors will know such moments. There is a glimpse of connection that is potentially healing and powerful. But why? The answer provides a clue to a notion of health that is not only about an absence of symptoms, valuable though that most certainly is. With a patient who feels heard, you together enter a field of existence that is wider than the previously isolated, suffering soul knew was possible. A dimension of life, not determined by having solutions, is discovered as a release or expansion. The word “health” itself recognises the possibility as it comes from the old English for “whole”. Believers in God will recognise that wholeness as an intuition: our existence as individuals is actually a sharing in the existence of God. We are as many reflections of the one divine light. A shift of perspective, a kind of conversion, is required for this transcendent awareness to become a steady part of life. The difference with this fuller notion of health or wholeness is that you don't privately possess it, let alone control it, but rather it holds you and you might collaborate with it more fully. The NHS will likely continue to struggle with the demands it faces, even as - and perhaps because - remarkable improvements in treatments will continue, too. In this context, a cultural and spiritual conversation about the wider nature of health is crucial. Like the patient who feels better because they are heard, a more expansive vision of what health entails, and indeed what it is to live well, will alleviate stresses on us all.

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest on Ozempic, from medical breakthroughs to lifestyle impacts.Listeners, big news from the British Heart Foundation: over one million people with cardiovascular disease will soon get Wegovy, which contains semaglutide like Ozempic, on the National Health Service to prevent heart attacks and strokes. The National Institute for Health and Care Excellence recommends it for those with a body mass index of twenty-seven or higher who have had a heart attack, stroke, or severe artery issues. Clinical trials show it cuts cardiovascular risks, independent of weight loss, and it's given as a weekly injection with diet and exercise.The Obesity Medicine Association reports that in December twenty twenty-five, the Food and Drug Administration approved an oral Wegovy pill for obesity, starting at one point five milligrams and titrating up. It matches the injectable's side effects like stomach issues but offers a no-needle option, taken on an empty stomach.Tirzepatide, sold as Zepbound, leads in effectiveness per their data, with up to twenty-two point five percent average weight loss in trials, beating semaglutide's fourteen point nine percent. Expect one to two new GLP-one drugs yearly from twenty twenty-six, like Lilly's orforglipron oral pill showing eleven point two percent loss, and Novo Nordisk's amycretin with twenty-four point three percent in phase two.Beyond weight, Advisory Board notes semaglutide's approvals for chronic kidney disease in type two diabetes patients and cardiovascular benefits, reducing major events by twenty percent. Studies link it to lower cognitive decline risks and possible fertility boosts from weight loss improving hormones.Always pair these with healthy eating, exercise, and behavioral changes for best results and to preserve muscle.Thanks for tuning in, listeners. Subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

In this episode of Dean's Chat, Dr. Jeffrey Jensen and Dr. Joanna Richey welcome Professor Dr. Lyndon Mason, an internationally recognized foot and ankle orthopedic surgeon based in the United Kingdom. The conversation offers a comprehensive look at his career journey, the structure of UK surgical training, and the foundational principles that have guided his success in clinical practice, research, and education.Dr. Mason, shares insights into his early path into medicine. Unlike the United States, where pre-medical education precedes medical school, Dr. Mason entered medical training directly at age 18. He outlines the UK system, which includes medical school, foundation years, core surgical training, registrar-level specialization, and fellowship.A central theme throughout the discussion is the profound impact of mentorship. Dr. Mason credits several key mentors with shaping his career trajectory, not only by providing guidance but also by challenging him to pursue opportunities beyond his comfort zone. He emphasizes that mentorship is not a short-term relationship but a lifelong influence, often continuing decades after initial training. These relationships also play a critical role in helping trainees navigate self-doubt and imposter syndrome—an experience Dr. Mason openly acknowledges as part of professional growth.Dr. Mason's career has been marked by extensive international experience, including training and observerships in Australia, Germany, and the United States. These opportunities exposed him to high-volume, complex pathology and diverse surgical approaches. Importantly, he highlights that the greatest value of these experiences lies not just in learning surgical techniques, but in understanding how different systems and surgeons approach problem-solving and patient care.With over 300 publications and more than 50 awards, Dr. Mason's academic productivity is driven by what Dr. Richey calls “insatiable curiosity.” He underscores the importance of questioning established practices, encouraging trainees to ask “why” at every step rather than accepting tradition at face value.The discussion also explores differences between the UK and U.S. healthcare systems, particularly in relation to industry collaboration. Dr. Mason explains that opportunities for device development and commercialization are more limited within the UK's National Health Service, where intellectual property is often institutionally held. As a result, relationships with industry differ significantly from those in the United States.Education remains a cornerstone of Dr. Mason's career. He describes a deep passion for teaching, especially at the level of early learners, and has developed numerous educational resources over time. During the COVID-19 pandemic, he launched a YouTube channel to make high-quality lectures accessible to trainees who might otherwise be restricted by paywalls. For him, teaching and curiosity are inherently linked—those who are driven to learn are naturally inclined to teach.Ultimately, Dr. Mason finds the greatest fulfillment in mentorship and the success of his trainees. He takes pride in seeing students progress through their careers, with the hope that they will surpass his own accomplishments. This long-term investment in others reflects his broader philosophy of growth, both personal and professional.The episode concludes with advice for students and early-career professionals. Dr. Mason encourages aspiring clinicians to question everything, work diligently, and pursue opportunities with persistence. He emphasizes that background does not define potential, and that growth often occurs in moments of discomfort. Hard work, curiosity, and a willingness to step outside one's comfort zone, he notes, are the keys to building a meaningful and impactful career.

United Kingdom correspondent Lucy Thomson spoke to Lisa Owen about how Donald Trump has taken aim again at the UK and how the National Health Service is starting to encounter shortages as a result of the Iran war. She also spoke about how Donald Trump is set to meet King Charles.

In this episode of JCO Article Insights, host Dr.  Ash Gurumurthi summarizes JCO articles, "Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study" and " Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma" TRANSCRIPT Ash Gurumurthi: Hi and welcome to JCO Article Insights. I'm your host, Ash Gurumurthi, and today we will be discussing two articles, both published in the Journal of Clinical Oncology, on the real-world utility of circulating tumor DNA (ctDNA) MRD in newly diagnosed large B-cell lymphoma. The first study is the article "Phased-Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study" by Dr. Joanna Krupka and colleagues in the United Kingdom. For the sake of convenience, I'll refer to this as the DIRECT study. The second study is "The Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma" by Dr. Steven Wang and colleagues in the Netherlands, referred to as the HOVON 902 study. By way of background, I wanted to talk about MRD in hematolymphoid malignancies. Nodal diseases have lacked a robust biomarker for end-of-treatment response. They have relied historically on PET scans interpreted using the semiquantitative Deauville 5-point scale, which has a high negative predictive value but a limited positive predictive value. The poor positive predictive value for survival results in extended follow-up with serial imaging for risk stratification with unnecessary and invasive biopsies. There have been recent revolutionary advancements in ctDNA MRD in B-cell lymphoma. The use of ctDNA in lymphoma began with CAPP-seq, which tracked single nucleotide variants that were tumor specific but was limited by excessive background sequencing noise with false negatives. To overcome this, Dr. Kurtz and colleagues developed the proprietary PhasED-seq assay. This tracks well-recognized phased mutations on the same DNA strand in cis configuration within hypermutated regions that are unique to B-cell lymphoma. Using this method, they pushed their limit of detection at 95%, the so-called LOD95, to 0.7 parts per million under optimal circumstances with 120 nanograms of input cell-free DNA from plasma. Based on the use of the PhasED-seq assay in trials of newly diagnosed large B-cell lymphoma with the use of investigational agents, the NCCN currently recommends consideration of ctDNA MRD assay with a detection limit of less than 1 part per million if biopsy is not feasible for a positive end-of-treatment PET. However, I believe this threshold needs reconsideration given it is based on an ideal assay LOD95 under optimal circumstances rather than sample-specific LOD95. Real-world validation of the role of end-of-treatment ctDNA and appropriate thresholds for sample-specific LOD95 were lacking until the publication of these two studies. The DIRECT and the HOVON 902 studies were multicenter, prospective trials using real-world cohorts of newly diagnosed large B-cell lymphoma treated with standard anthracycline immunochemotherapy, ie, R-CHOP chemotherapy. They validated end-of-treatment ctDNA MRD response measured on a phased-variant platform and found them to be strongly prognostic for relapse and survival. This was independent of PET imaging or baseline clinical prognostication like the International Prognostication Index, the IPI. They also demonstrated a threshold with an LOD95 of approximately 1 in 100,000 is necessary for clinical utility. Both trials recruited over a similar period between 2020 to 2023, with the DIRECT study conducted within the National Health Service in the United Kingdom and the HOVON 902 as a national study in the Netherlands. For survival analysis, only patients who reached the landmark event of end of treatment with an available ctDNA MRD sample without progressive disease or death at that time point were included. These studies evaluated similar-sized cohorts with 134 patients for HOVON 902 and 151 patients for the DIRECT study. As expected, their baseline demographics are reflective of a real-world population of newly diagnosed cases with large B-cell lymphoma. Although both used comparable statistical methodologies with time-to-event analysis, the primary outcomes vary, making headline comparisons quite challenging. The DIRECT study utilized the time to tumor progression, censoring death unrelated to disease. This was done to isolate the molecular impact of detectable ctDNA at the end of treatment. In contrast, the HOVON 902 study used progression-free survival, which counts all-cause mortality as an event. This naturally results in lower event-free rates for PFS compared to TTP in the DIRECT study. The trials differed in their choice of phased-variant platforms, with the DIRECT study developing an independent, fully open-source phased-variant ctDNA assay. This has been released on GitHub. In contrast, the HOVON 902 study utilized PhasED-seq by Foresight Diagnostics, which is currently the only proprietary and commercially available phased-variant assay for lymphoid malignancies. Interestingly, despite the differences in platforms and the primary end points, the results were remarkably consistent. The DIRECT study found a highly significant difference in the 2-year TTP rate of 96% in those with undetectable ctDNA MRD at the end of treatment compared to 45% in those with detectable ctDNA, with a hazard ratio of 15. Similarly, the HOVON 902 study found a significantly superior 3-year PFS of 85% in those with undetectable ctDNA compared to 17% with detectable ctDNA, with a hazard ratio of 10. Crucially, both studies found end-of-treatment ctDNA MRD significantly outperformed PET response assessment for long-term PFS. In fact, for the end point of PFS in both trials, the baseline IPI lost all statistical significance in both univariate and multivariable analysis when accounting for ctDNA MRD and PET status at the end of treatment. While both studies demonstrate the superiority of ctDNA MRD compared to PET in predicting survival, interestingly, the combination of both tests appeared to be complementary in identifying the highest-risk group. The HOVON 902 study identified 13 patients who were double positive, ie, they were positive with end-of-treatment PET and detectable ctDNA MRD. Every single one of these patients progressed over a 3-year period with a dismal overall survival of 17%. The DIRECT study mirrored these findings with the same double-positive group having a 2-year time to progression rate of 23%. Given consistency in identifying the poor outcome of this double-positive population in both studies, this is clearly a group that would benefit from trial-based approaches like consolidation or, alternatively, frequent surveillance for clinical relapse. On the other hand, the best-performing group was the double negative, ie, those who had achieved PET negative and ctDNA undetectable at the end of treatment. The double-negative group had a 2-year time to progression of 97% in the DIRECT study and a 3-year PFS of 88% in the HOVON 902 trial. This is quite impressive. Based on these findings, we can anticipate that ctDNA may complement rather than wholly replace PET at the end of treatment for response assessment. Perhaps the most critical finding from both studies challenged current NCCN-recommended ctDNA MRD sensitivity threshold of achieving less than one part per million. While phased-variant assays can theoretically detect this, this is under optimal conditions, specifically 120 nanograms of input cell-free DNA. In both trials, only 3% of samples could achieve this sensitivity, with the vast majority limited to a sample-specific LOD95 of approximately 1 in 100,000 informative reads. The primary constraint was simply limited plasma volume collected, a denominator problem of input cell-free DNA. For example, the HOVON 902 study had a median plasma volume of 5 mL, yielding 20 nanograms of input DNA. The DIRECT study elegantly demonstrated bridging the gap to attain the NCCN standard of LOD95 of less than 1 part per million is practically impossible. This would require greater input DNA, attained through a 20- to 30-milliliter collection of plasma rather than the standard 10 milliliters, and a massive 20- to 40-fold increase in sequencing depth. With the current real-world sensitivity of roughly 1 in 100,000 in both these studies, the negative predictive value is already nearly at 90%. There is going to be diminishing returns for further analytical sensitivity. This strongly suggests that the NCCN guidelines should be updated to prioritize achievable sample-specific LOD95 rather than assay-specific theoretical limits. Collectively, these studies validate the real-world utility of ctDNA MRD as an independent predictor of long-term outcomes following first-line therapy of large B-cell lymphoma. Finally, after two decades of the default R-CHOP for all, the field of aggressive large B-cell lymphoma is taking leaps and bounds by integrating ctDNA MRD with the current wave of bispecific and cellular therapies. I want to now leave you with my five key clinical takeaways from both these studies. ●        Firstly, ctDNA MRD is a more potent independent predictor of outcome than end-of-treatment PET/CT and baseline IPI. ●        Second, ctDNA MRD in first-line large B-cell lymphoma is already reshaping clinical trial space with therapeutic escalation and de-escalation strategies based on ctDNA kinetics during treatment, as well as identifying candidates with persistent ctDNA at the end of treatment for consolidation approaches. ●        Thirdly, this technology is ready for prime time. Whether this is through Foresight's PhasED-seq assays or the open-source method released by the DIRECT group, academic centers can now operationalize this in routine clinical care. ●        Fourth, biology clearly provides a ceiling. Current sensitivity goals of less than one part per million as recommended by the NCCN are limited by the actual amount of cell-free DNA we can extract from a patient's blood, not just the assay's technology. I believe these two studies will inform the NCCN's next revision to move away from theoretical assay limits to a more realistic sample-specific LOD95 of approximately 1 in 100,000. ●        Finally, it appears that the end-of-treatment ctDNA MRD test may be complementary to PET/CT rather than a replacement. Clearly, the best outcomes are seen in double-negative patients, while double-positive results, ie, positive end-of-treatment PET and detectable ctDNA at the end of treatment, identify a group with an extremely high risk of early progression who may need early intervention. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Moira Newiss spent 20 years running hospitals for the UK's National Health Service before her body and mind staged a slow, invisible collapse that no blood panel could explain — and the system she'd devoted her career to had nothing to offer but a prescription she didn't want to fill. What she found instead was a framework rooted in mitochondrial biology that reframes mental illness, chronic fatigue, and burnout as problems of cellular energy rather than brain chemistry. BIG IDEA"Psychological stress adversely affects the mitochondria just like high-sugar diets do — and a ketogenic diet can correct things that psychological interventions alone sometimes cannot."Moira Newiss Contact InfoWebsite: moiranewiss.co.ukLinkedIn: Moira NewissYouTube: https://www.youtube.com/@moiranewissChange.Org : Overhaul the UK dietary GuidelinesSend Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Pre-Order Stay Off My Kitchen Table at Amazon. Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Stay Off My Operating Table on X:   Dr. Ovadia: @iFixHeartsJack Heald: @JackHeald5Learn more:Stay Off My Operating Table on AmazonTake Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart HealthJack Heald's website: CultYourBrand.comTheme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

The Brazilian Butt Lift surgery is one of the fastest growing cosmetic surgeries in the world, but it is also one of the most dangerous. The risk of death from having a BBL is at least 10 times higher than many other procedures – that's according to the UK's National Health Service. In several countries in Africa, the demand for BBLs is on the rise, but there are still challenges around regulation. Just recently in Lagos, a young woman reportedly died after a BBL procedure, prompting Nigeria's Lagos State Government to launch an investigation into her death. In this episode, we hear from two young women, in Kenya and Nigeria, who recently got BBLs to hear about the risks, the post-surgery recovery and the influence of social media on body image.Presenter : Nkechi Ogbonna Producers: Fana Negash Technical Producer: Mbarak Abdallah Senior Producers: Carolyne Kiambo Jotham and Priyanka Sippy Editors: Samuel Murunga and Maryam Abdalla

United Kingdom correspondent Lucy Thomson spoke to Lisa Owen about the findings from the UK Covid-19 Inquiry revealing the National Health Service was 'on the brink of collapse' during the pandemic, as well as health officials currently struggling to keep up with demand for students seeking the Meningitis B vaccine.

Arts On Prescription: What if your doctor prescribed an arts-based treatment for what ails you and your health insurance paid for it.YEAH RIGHT! Actually, Yeah, right, and REALLY! In this episode we learn all about it in Arts on Prescription: A Field Guide for U. S. CommunitiesBIO'sDr. Tasha Golden directs research for the International Arts + Mind Lab at Johns Hopkins Medicine. As a national leader in arts + public health, Dr. Golden studies the impacts of arts & culture, music, aesthetics, and social norms on well-being, health research, and professional practice. She has authored many publications related to arts and health, served as an advisor on several national health initiatives, and is adjunct faculty for the University of Florida's Center for Arts in Medicine.In addition to her research, Golden is a career artist and entrepreneur. As singer-songwriter for the critically acclaimed band Ellery, she toured full-time in the U.S. and abroad, and her songs appear in feature films and TV dramas (ABC, SHOWTIME, FOX, NETFLIX, etc). She is also a published poet and has taught university courses in public health as well as in writing, rhetoric, and literature. Holding a Ph.D. in Public Health Sciences, Dr. Golden draws on her diverse background to develop innovative, interdisciplinary presentations and partnerships that advance health, health equity, creativity, and well-being.Dr. Golden is also the founder of Project Uncaged: an arts-based health intervention for incarcerated teen women that amplifies their voices in community and policy discourses. These young folx are among her greatest teachers.Jill Sonke, PhD, is director of research initiatives in the Center for Arts in Medicine at the University of Florida (UF), director of national research and impact for the One Nation/One Project initiative, and co-director of the EpiArts Lab, a National Endowment for the Arts Research Lab. She is an affiliated faculty member in the UF School of Theatre & Dance, the Norman Fixel Institute for Neurological Diseases, the Center for African Studies, the STEM Translational Communication Center, and the One Health Center, and is an editorial board member for Health Promotion Practice journal. She served in the pandemic as a senior advisor to the US Centers for Disease Control and Prevention (CDC) Vaccine Confidence and Demand Team on the COVID-19 Vaccine Confidence Task Force and currently serves on the steering committee of the Jameel Arts & Health Lab, established by the World Health Organization (WHO), the Steinhardt School at New York University, Community Jameel, and CULTURUNNERS.With 28 years of experience and leadership in the field of arts in health and a PhD in arts in public health from Ulster University in Northern Ireland, Jill is active in research and policy advocacy nationally and internationally. She is an artist and a mixed methods researcher with a current focus on population-level health outcomes associated with arts and cultural participation, arts in public health, and the arts in health communication. Notable MentionsNotable MentionsArts On Prescription: A Field Guide for US Communities.: A roadmap for communities to develop programs that integrate arts, culture, and nature resources into local health and social care systems. prescription Anne Basting, Creative Care: Basting pioneers a radical change in how we interact with older loved ones, especially those experiencing dementia, as she introduces a proven method that uses the creative arts to bring light and joy to the lives of elders.Atlantic Fellowship:Through seven global, interconnected programs, Atlantic Fellows collaborate across borders and disciplines to address the root causes of inequity.Veronica Rojas is an Atlantic Fellow who works in different art programs in the San Francisco Bay Area that either serve adults with developmental disabilities or older adults, many with dementia. She is both a practicing and teaching artist.Center for Arts in Medicine at the University of Florida (UF): Using creativity to advance health, wellness, and equity as a trained arts in health professional. Promote health one creative moment at a time.International Arts + Mind Lab at Johns Hopkins Medicine,Tennessee Whiskey, Tasha Golden, from Over Land, Over SeaInterlochen Arts Academy: “A global community of like-minded artists, you'll discover a high school for the arts (grades 9-12) you may only have dreamed about.”Mass Cultural Council, CultureRX: Mission - To build a public infrastructure that supports the role of cultural experiences as a protective factor in the health and well-being of all people in the Commonwealth.United Kingdom, National Health Service, social prescribing infrastructure is an approach that connects people to activities, groups, and services in their community to meet the practical, social and emotional needs that affect their health and wellbeing.. Alan Siegel advocate for social prescribingHorizon Blue Cross Blue Shield in New Jersey/New Jersey Performing Arts Center: Horizon Blue Cross Blue Shield of New Jersey has made a $3 million gift to NJPAC to support new arts and wellness programming both at the Arts Center and throughout Newark. Health Organization's definition of health, World Health Organization published a social prescribing toolkit.Federal Reserve Bank of New York/Social Prescribing: On Wednesday, October 4, 2023, the Federal Reserve Bank of New York, in partnership with Social Prescribing USA, hosted an in-person event discussing how medical prescriptions for patients to participate in community activities such as walking in nature, creating and viewing art, joining social groups, and volunteering can improve public health.Quebec, Mediateur Culturel, For several years, the City of Quebec has been developing cultural mediation projects between professional artists and citizens. By bringing art into their living environment and involving them in the creative process, cultural mediation places citizens at the heart of the artistic process. Here are the works of art created so far in all the boroughs of Quebec.Dr. Daisy Fancourt, is a British researcher who is an Associate Professor of Psychobiology and Epidemiology at University College London.[3][4][5] Her research focuses on the effects of social factors on health, including loneliness, social isolation, community assets, arts and cultural engagement, and social prescribing.[6Social Prescribing USA: “Our mission is to make social...

Cybercrime's escalation has reached a projected $12.2 trillion annual impact by 2031, with a notable surge in remote monitoring and management (RMM) tool abuse—up 277% year-over-year, according to Huntress and supporting vendor reports. Attackers utilize legitimate IT tools to facilitate stealthier ransomware and phishing campaigns, amplifying structural vulnerabilities within MSP technology stacks. Key metrics from Acronis, WatchGuard, and Vectra AI indicate a shift to smaller, more evasive malware campaigns, longer times to ransomware deployment (averaging 20 hours), and widespread unaddressed security alerts, raising questions about the adequacy of current defenses and incident response practices. Vendor-supplied threat intelligence further shows that MSPs' reliance on signature-based platforms and insufficient visibility leaves them exposed to evolving attack techniques. Data reviewed suggests phishing footholds can quickly compromise cross-client environments, and legal ramifications heavily fall on the service provider when RMM or monitoring tools act as entry points. Notably, only about 58-60% of organizations report full visibility across their systems, with a majority of alerts remaining unaddressed, underscoring gaps in operational maturity and preparedness. Adjacent coverage highlighted Microsoft Copilot's repeated security control failures within regulated environments, specifically its inability to enforce sensitivity labels and boundaries across emails—most recently affecting the UK's National Health Service. The lack of vendor-announced architectural changes calls into question the viability of deploying AI tools in compliance-driven contexts. Separately, political and public backlash against surveillance technologies (such as Flock cameras) demonstrates that unchecked data collection is no longer a manageable passive risk, as data becomes increasingly actionable and retains liability beyond technical considerations. The practical takeaway for MSPs and IT leaders is a need to prioritize audit, documentation, and enforcement of controls within their technology stacks, especially where vendor tools or AI-driven automation intersect with compliance and client trust. Preserving operational optionality and scrutinizing vendor terms—particularly data sharing and architectural enforcement—are essential to reduce exposure. Waiting for vendor patches, disregarding documented control failures, or underestimating public scrutiny elevate liability across legal, reputational, and client relationship domains. Four things to know today: 00:00 Vendor Threat Reports Converge on One Risk MSPs Can't Outsource: The RMM as Breach Vector 05:11 Copilot Failed Compliance Controls Twice in Eight Months — A Patch Won't Fix That 07:03 Flock Backlash Exposes the Liability Hidden in Every Vendor Data-Sharing Contract 09:42 GTDC Summit: Distributors Pitch AI On-Ramp as Hyperscalers Compress Their Margin Sponsored by:  

Is your teen's behavior a sign that something is “wrong”… or could it be part of normal development in a high-pressure world?When should parents seek help—and when might labels actually do more harm than good? In this powerful and thought-provoking episode, Colleen O'Grady sits down with child and adolescent psychiatrist Dr. Sami Timimi, author of Searching for Normal. With over 35 years in the UK's National Health Service, Dr. Timimi challenges many of the assumptions parents have been taught about teen mental health. Together, they explore why diagnoses like ADHD, autism, anxiety, and depression have exploded—and why medicalizing distress can sometimes steal hope instead of restoring it. This conversation reframes teen behavior through the lens of context, development, relationships, and resilience, reminding parents that emotions are not emergencies and that most teens are not broken—they're responding to a stressful world. About Dr. Sami Timimi Dr. Sami Timimi is a British child and adolescent psychiatrist with more than three decades of clinical experience in the UK's National Health Service. He has authored numerous academic papers and books and is widely known for his critiques of the over-medicalization of mental health. In Searching for Normal, Dr. Timimi offers a deeply humane, evidence-based challenge to psychiatric labeling and invites families to reclaim a more hopeful, relational understanding of distress. Three Takeaways for Parents Distress is not the same as disorder. Many teen struggles are understandable responses to pressure, change, and context—not signs of lifelong pathology. Labels shape identity—and not always in helpful ways. Diagnoses can unintentionally limit teens, increase fear, and turn temporary struggles into permanent stories. Relationships matter more than control. Teens don't need to be “fixed”—they need connection, patience, and adults who aren't afraid of emotions. Follow at: https://www.instagram.com/dr_samitimimi/?hl=en Learn More at: https://www.samitimimi.co.uk/ Learn more about your ad choices. Visit megaphone.fm/adchoices

FOLLOW RICHARD Website: https://www.strangeplanet.ca YouTube: @strangeplanetradio Instagram: @richardsyrettstrangeplanet TikTok: @therealstrangeplanet EP. #1313 Murdered by Protocol: COVID and the NHS Death Machine For years, we were told the greatest threat to humanity was a virus. But what if the real danger wasn't the pathogen—it was the protocol? Tonight on Strange Planet, Richard Syrett ventures into one of the darkest, least examined chapters of the COVID era. Drawing on firsthand testimony, medical records, and hard data, this episode investigates allegations that thousands of vulnerable patients in the UK's National Health Service may not have died from COVID, but because of policy-driven medical decisions. Sedation. Isolation. Denial of treatment—carried out under emergency authority and bureaucratic language. GUESTS: Jacqui Deevoy is an investigative journalist and filmmaker who spent decades writing for Britain's mainstream press before becoming persona non grata for asking forbidden questions. During the COVID era, she uncovered alarming patterns inside UK hospitals and care homes—blanket DNR orders, family exclusion, and the widespread use of end-of-life drugs on non-terminal patients. After the sudden death of her own father, Deevoy compiled testimonies from 42 families into Murdered by the State, a chilling civilian record of alleged involuntary euthanasia carried out under emergency powers. Richard Cox is an author, researcher, and host of The Deep State Consciousness Podcast. As co-editor of Murdered by the State, Cox provides the book's analytical backbone, examining excess mortality data, NHS protocols, drug procurement records, and historical precedents like the Liverpool Care Pathway. His work frames the COVID death surge not as medical chaos, but as systemic compliance—raising disturbing questions about how policy, not pathology, may have driven outcomes, and why those powers never fully disappeared. WEBSITES/LINKS: https://substack.com/@jacquideevoy https://www.deepstateconsciousness.com BOOK: Murdered by the State: Involuntary Euthanasia in Plain Sight SUPPORT OUR SPONSORS!!! QUINCE Luxury, European linen that gets softer with every wash! Turn up the luxury when you turn in with Quince. Go to Quince dot com slash RSSP for free shipping on your order and 365-day returns. Now available in Canada, too. BECOME A PREMIUM SUBSCRIBER!!!⁠ ⁠https://strangeplanet.supportingcast.fm⁠ Three monthly subscriptions to choose from. Commercial Free Listening, Bonus Episodes and a Subscription to my monthly newsletter, InnerSanctum. Visit ⁠https://strangeplanet.supportingcast.fm⁠ Use the discount code "Planet" to receive $5 OFF off any subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit ⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

It's Thursday, January 22nd, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com. I'm Adam McManus. (Adam@TheWorldview.com) By Jonathan Clark Chinese-American Christians pray for those in China Chinese-American Christians are praying for their persecuted brothers and sisters back in China. Earlier this month, Harvest Chinese Christian Church in Los Angeles held an event called “Fasting Prayer Meeting for Persecuted Churches in China.” The event comes shortly after Chinese authorities detained the leaders of Early Rain Covenant Church. The congregation, like many “unregistered” churches in China, faces relentless persecution. International Christian Concern commented, “Please pray for these house church members in China, especially those who have been imprisoned or are missing after the police raids.” 1 Corinthians 12:26 says, “If one member suffers, all the members suffer with it; or if one member is honored, all the members rejoice with it.” China's birth rate plunged to a record low in 2025 Speaking of China, the country's birth rates plunged to a record low in 2025. New data from China's National Bureau of Statistics found there were 7.92 million births last year, down 17% from 2024. The birth rate in 2025 was 5.63 per 1,000 people. Meanwhile, the death rate rose to 8.04 per 1,000 people. Despite China's recent attempts to incentivize families to have children, the population has now fallen for the fourth consecutive year. In Genesis 1:28, God commanded, “Be fruitful and increase in number; fill the Earth and subdue it.” British Christian nurse vindicated for calling a man “Mister” In the United Kingdom, a National Health Service hospital recently dropped its case against a Christian nurse. Jennifer Melle worked at St. Helier Hospital in south London. She faced suspension after referring to a man, pretending to be a woman, as “Mister.” Listen to comments she made after her vindication. MELLE: “I am deeply relieved and grateful to hear that St Helier [Hospital] has confirmed it would no longer take further action against me. This has been an incredibly long and painful journey.   “Today, I want to give thanks, first and foremost, to our Lord and Savior, Jesus Christ, who has sustained me every step of the way.” Young Canadians are planning to vote conservative Young adults in Canada are planning to vote conservative in the country's next election. A survey by Abacus Data found 50% of Canadians aged 18 to 29 would vote for the Conservative Party. Only 27% of that demographic would vote for the Liberal Party. The strongest support for the Liberals comes from people over 60. A decade of liberal polices has led to higher living costs, higher inflation, and higher taxes. Trump: “I will not use force” to get Greenland Yesterday, U.S. President Donald Trump addressed the World Economic Forum's annual meeting in Davos, Switzerland.  Notably, he announced that the United States would not use force to acquire Greenland. TRUMP: “We probably won't get anything unless I decide to use excessive strength and force, where we would be, frankly, unstoppable. But I won't do that. Okay. Now everyone's saying, ‘Oh, good!' “That's probably the biggest statement I've made because people thought I would use force. I don't have to use force. I don't want to use force. I won't use force.” President Trump also announced he will not be imposing tariffs on Denmark over the acquisition of Greenland. He wrote on Truth Social, “We have formed the framework of a future deal with respect to Greenland and, in fact, the entire Arctic Region.” Arrests coming for Minneapolis leftists who invaded church service The Trump administration is investigating anti-ICE protesters who disrupted a house of worship in Minneapolis on Sunday. Kristi Noem, the Department of Homeland Security Secretary, wrote on X, “Arrests coming. … The First Amendment protects speech and peaceful assembly – not rioting. … These agitators will be held accountable.” The Department of Justice is also investigating the incident at Cities Church. Major snowstorm hits East Coast to Rocky Mountains The National Weather Service is expecting a significant winter storm to hit a large portion of the U.S. starting Friday. Heavy snow, sleet, and freezing rain is forecast all the way from the southern Rockies to the East Coast.  Much of the U.S. is already experiencing dangerously cold weather. Over 40 million people were under cold weather alerts as of Tuesday. Even parts of Florida are under alert. 463rd anniversary of Heidelberg Catechism And finally, this week marks the 463rd anniversary of the Heidelberg Catechism. The Protestant catechism was commissioned by Frederick III, the ruler of Germany's most influential province of Palatinate. The purpose of the catechism was for instructing the youth and for guiding pastors and teachers The catechism was the product of two young Protestant scholars—Zacharius Ursinus and Caspar Olevianus. The catechism was approved by a church synod in Heidelberg, Germany and published in German on January 19, 1563. It would become the most widely used catechism of the Reformation period.  The catechism's opening question reads, “What is your only comfort in life and death?” The answer begins, “That I am not my own, but belong—body and soul, in life and in death—to my faithful Savior Jesus Christ.” Romans 14:8 says, “For if we live, we live to the Lord; and if we die, we die to the Lord. Therefore, whether we live or die, we are the Lord's.”  Close And that's The Worldview on this Thursday, January 22nd, in the year of our Lord 2026. Follow us on X or subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in CFS and ME. Show partners:  LMNT - Claim your free LMNT Sample Pack with any purchase by using this link Ketone-IQ - Save 30% off your subscription order plus youʼll get a free gift with your second shipment by using this link Troscriptions - 10% off your first order by using the code "JESSE" at checkout Quicksilver Scientific - 15% off your first order by using the code "jesse15" at checkout Show notes: https://jessechappus.com/688

Send Vikki any questions you'd like answered on the show!A critical inner voice is one of the most common and difficult experience as a PhD student or academic. In this episode, you get to hear me coaching TWO of my current students in the PhD Life Coach membership, who are both part time PhD students while holding down demanding careers in our National Health Service. It runs like one of our group coaching sessions, where they each get coached AND hear each other get coached on self-talk, prioritisation, and compassion. If you have a critical inner voice, or if you've ever wondered about the benefits of group coaching, then you're in the right place!If you liked this episode, you should check out my episode on How Winnie the Pooh can help you manage your mind.****I'm Dr Vikki Wright, ex-Professor and certified life coach and I help everyone from PhD students to full Professors to get a bit less overwhelmed and thrive in academia. Please make sure you subscribe, and I would love it if you could find time to rate, review and tell your friends! You can send them this universal link that will work whatever the podcast app they use. http://pod.link/1650551306?i=1000695434464 I also host a free online community for academics at every level. You can sign up on my website, The PhD Life Coach. com - you'll receive regular emails with helpful tips and access to free online group coaching every single month! Come join and get the support you need.

In this episode, we tackle the contentious issue of socialized medicine in America, with a spotlight on the failures of the National Health Service in Great Britain. John Solomon welcomes former British Prime Minister Liz Truss, who shares her firsthand experiences and insights into the pitfalls of government-run healthcare. We also discuss the implications of free speech in today's political climate with author Stuart Brotman. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Alexandra Markou-Guzman is a pediatric dentist who works in a public health center treating children from a Hasidic Jewish population in New York City. She shares her experience working with this population, and the cultural challenges that come with it. We discuss some of the unique dental considerations that come into play with treatment planning and working with these families. Dr. Alex is a recent graduate of an NYU residency. She shares how she was able to apply for and receive a National Health Service scholarship to help pay for school. By qualifying for this scholarship and completing two years of work in public health, she was able to significantly reduce her student loan burden.

Welcome to the Planet MicroCap Podcast's Due Diligence series. I'm your host, Robert Kraft. My guest today is Dan Goldberger, CEO of electroCore (NASDAQ: ECOR). electroCore is a commercial-stage neuromodulation company developing a suite of non-invasive vagus nerve stimulation devices—delivering a two-minute therapy session designed to rebalance the autonomic nervous system. Built around its nVNS platform, the company operates across three channels: prescription medical devices for headache and migraine, the fast-growing Truvaga direct-to-consumer wellness brand, and a specialized military and government division built around its ruggedized tac-stim product.   Founded in 2006 as a non-invasive alternative to implanted vagus nerve stimulators, electroCore has evolved into a multi-indication business with seven FDA authorizations for headache, serving major customers like the U.S. Department of Veterans Affairs and the UK's National Health Service. I invited Dan to the show to discuss all of this, as well as: How nVNS platform works and the science behind vagus nerve modulation electroCore's evolution from implanted alternatives to multi-channel neuromodulation The prescription business model across the VA, NHS, and managed care Truvaga's growth in the wellness market and why awareness is the primary competitor The tac-stim military program and its role as a meaningful revenue stream Strategic priorities heading into 2026—profitability, capital allocation, and commercial execution Challenges around insurance coverage and overcoming the “chicken and egg” problem The path toward becoming a $150–200 million business and the long-term vision for the platform For more information about electroCore, please visit: https://www.electrocore.com/ This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action. The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast. SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL'S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST. By accessing this podcast, the listener acknowledges that the entire contents and design of this podcast, are the property of SNN, or used by SNN with permission, and are protected under U.S. and international copyright and trademark laws. Except as otherwise provided herein, users of this podcast may save and use information contained in the podcast only for personal or other non-commercial educational purposes. No other use, including without limitation, reproduction, retransmission, or editing of this podcast may be made without the prior written consent of SNN.

In case you didn't see our major announcement this week… The OCTOBER 7 play is having its most high profile performance to date! You won't believe where it will be showing next. Hint: It's right in the belly of the beast and we want to see you there. All will be revealed soon. And just when we thought the trans madness was dying in the UK, we discover that the Dr Frankensteins/Mengeles of the world are alive and well in that country's National Health Service. They want to recruit 250 humans for gender experiments.Oh but don't worry, these patients/victims will be at least at the ripe old age of 10, and totally understand what they're in for. Of course they can give informed consent. Not. Watch the Scoop this week to hear about the latest attack on children whose bodies are being destroyed on the altar of progress. And our home country of Ireland is constantly proving that it is the most anti-Semitic country in Europe. Now they've somehow sunk to a new low by deciding to rename a park, which was dedicated to a local Jewish hero. Dublin City Council's scheme was thwarted by a technicality, for now… Watch this week's episode to get all of the infuriating details. You can also learn more through Phelim's coverage on Substack(linked below).And in Crazy California, we reveal why the homeless problem will never be solved. It's because Democrats are making just too much money maintaining the problem - as the rest of us suffer from their corruption.And is Ann McElhinney safe to drive on the nation's roads? According to the DMV - she is a danger. If it's true, then how did hundreds of thousands of Indian immigrants get truck driving licenses when they obviously were not qualified? Watch this week to hear our answer. And we have a new “no recipe recipe” for salmon this week. Watch this week to learn how to make one of Ann's favorite dishes. You will also need Ann's recipe for Kale Salad(linked below) for a side and we let you in on our secret for the perfect French Fries. For those who missed last week's episode, we looked back at the first Thanksgiving episode of the ANN AND PHELIM SCOOP when we interviewed our dear friend, Dennis Prager. Dennis, who has suffered a catastrophic injury, is the embodiment of the spirit of Thanksgiving and our interview with him and hearing his message promoting happiness and gratitude still warms the heart. Dennis has had a tough time since then, but he says he is still thankful to be alive. As you know we read all of your comments and loved all of the encouragement that you sent his way. We will be passing on your messages to Dennis.Watch the episode where we will read some of those comments on the air. Please keep leaving comments wherever you get our content and you may get a shoutout on our show. While you will be getting this message after Giving Tuesday, we do ask that you go to Unreportedstorysociety.com(also linked below) and give what you can so that we can keep producing new projects, and keep our latest projects like OCTOBER 7 the play running. We are a 501(c)(3) so your donation will be tax deductible.If you want to see OCTOBER 7 the play come to a location near you please donate at October7theplay.com(also linked below). And if you are already doing your Christmas shopping and waiting in another loooong line at the mall, please consider subscribing to our Stories.io substack(linked below) so that you can get informed and engaged in matters that we talk about beyond just our weekly show.To donate click here:To subscribe to our substack click here:To help us continue to tour OCTOBER 7 the play, please go here:http://October7thePlay.com To read Phelilm's latest substack about anti-Semitism in Ireland click here. To make Ann's kale salad recipe click here:

#656: What would you do if someone in authority told you to do something that felt wrong? Most of us like to think we'd speak up, push back, stand our ground. But research tells a very different story. In fact, when Yale researchers conducted a famous experiment in the 1960s, they found that 65% of people would administer what they believed to be deadly electric shocks to another human being... simply because someone in a lab coat told them to. Today's guest has spent over 15 years studying why humans comply with authority - even when every fiber of our being is screaming that we shouldn't. And when it comes to our money, this tendency to comply with authority figures - from financial advisors to real estate agents to car salespeople - can cost us dearly. Dr. Sunita Sah began her career as a physician in the UK's National Health Service. During one particularly exhausting period as a junior doctor, she agreed to meet with a financial advisor who had contacted her at work. That meeting sparked questions that would shape the rest of her career: Why did she feel pressured to trust this advisor, even after learning he had a conflict of interest? Today, she's a tenured professor at Cornell University, where her groundbreaking research on compliance and influence has been featured in The New York Times and Scientific American. She's advised government agencies, served on the National Commission on Forensic Science, and helps leaders understand the psychology behind why we say "yes" when we really want to say "no." Whether you're meeting with a financial advisor, negotiating the price of a home, or discussing rates with a contractor, understanding the psychology of compliance could save you thousands of dollars - and help you make better financial decisions. Today's conversation isn't just about psychology - it's about protecting your wealth by learning when and how to say "no." Resources Mentioned in the Episode: - Website: sunitasah.com - Newsletter: Defiant By Design | Dr. Sunita Sah | Substack - Connect with Dr. Sunita Sah - Follow Dr. Sah on Instagram About Dr. Sunita Sah Dr. Sunita Sah is a tenured professor at Cornell University specializing in organizational psychology. Her research focuses on how and why people comply with authority, even against their better judgment. A former physician in the UK's National Health Service, Dr. Sah brings a unique perspective to understanding human behavior and decision-making. Her work has been featured in leading publications including The New York Times and Scientific American, and she has served as a Commissioner on the National Commission on Forensic Science. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Aneurin Bevan's commitment to social justice led to the creation of the National Health Service in 1948 – one of the most ambitious social reforms in British history. He was an MP who stuck to his principles in the face of serious opposition, but was not without criticism in both his professional and personal life. Speaking to Lauren Good, Nye Davies charts Bevan's journey from the coalfields of South Wales to the corridors of Westminster. The HistoryExtra podcast is produced by the team behind BBC History Magazine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Roughly 1 in 10 Americans take antidepressants. The most common type is SSRIs, or  selective serotonin re-uptake inhibitors, like Prozac, Lexapro, and Zoloft. But what happens when you stop taking them? Studies don't point to a single conclusion, and there's ongoing debate among physicians and patients about the severity and significance of SSRI withdrawal symptoms. The discourse reached a fever pitch when Health Secretary Robert F. Kennedy Jr. compared SSRI withdrawal to heroin withdrawal in January.Host Flora Lichtman digs into the data on SSRI withdrawal with psychiatrists Awais Aftab and Mark Horowitz.Guests: Dr. Awais Aftab is a clinical associate professor of psychiatry at Case Western Reserve University.Dr. Mark Horowitz is a clinical research fellow in the UK's National Health Service and  scientific co-founder of Outro Health.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Story 1: The term “fascist” has become the go-to insult among politicians and political steamers as of late, but how many of them understand the definition behind it? Will breaks down what the true definition of fascism is and explains how its misuse can potentially embolden some to commit acts of violence. Story 2: Congressman Andy Barr (R-KY) joins Will to discuss the rise in support for socialism in Democrats across the country, and the ripple effect it has had amongst the Democratic Party's politics. Plus, Rep. Barr and Will react to a viral clip of Kentucky legend Colonel Sanders' great-great-great nephew denouncing KFC's risqué marketing, before proceeding to reveal what he claims are the secret 11 herbs and spices. Story 3: Host of ‘The Rubin Report,' Dave Rubin helps Will break down the bizarre support from the UK's National Health Service for first cousin marriage, which they now claim leads to stronger social support systems and economic advantages? Will and Dave examine how such a study could have been published despite overwhelming evidence suggesting that such marriages lead to birth defects, and what a sudden influx of Pakistani migrants has to do with it. Plus, in Final Takes, Will and The Crew share their thoughts on last night's tie between the Cowboys & the Packers, before discussing Bad Bunny being selected to headline the Super Bowl halftime show.     Subscribe to ‘Will Cain Country' on YouTube here: ⁠⁠Watch Will Cain Country! ⁠⁠Follow ‘Will Cain Country' on X (@willcainshow), Instagram (@willcainshow), TikTok (@willcainshow), and Facebook (@willcainnews) Follow Will on X: ⁠⁠@WillCain  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Dr. Sarah Myhill has worked full time in National Health Service and independent medical practice. She has a special interest in Chronic Fatigue Syndrome and ME. Show partners: Troscriptions - 10% off your first order by using the code "JESSE" at checkout Quicksilver Scientific - 15% off your first order by using the code "jesse15" at checkout Maui Nui Venison - Get yourself some high quality venison using this link Show notes: https://jessechappus.com/670

The number of people 85 years and older is expected to double in the U.K. over the next couple of decades. Apian, a London-based health care logistics company that partners with the National Health Service, thinks automation can help. We visit Apian to understand how automated robots could ease the burden of caring for an aging population. Also in this episode: A pilot pushes for menopause policies at British Airways, and an entrepreneur launches a skincare business at 50.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.